WO2005105060A1 - Plaster - Google Patents
Plaster Download PDFInfo
- Publication number
- WO2005105060A1 WO2005105060A1 PCT/JP2005/008035 JP2005008035W WO2005105060A1 WO 2005105060 A1 WO2005105060 A1 WO 2005105060A1 JP 2005008035 W JP2005008035 W JP 2005008035W WO 2005105060 A1 WO2005105060 A1 WO 2005105060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plaster
- mass
- water
- patch
- sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention relates to a patch.
- Patches such as knocking agents used as pharmaceuticals, knocking agents used as cosmetics or quasi-drugs, etc. are provided with sheet-like hydrogel bodies.
- the plaster base is formed into a sheet (for example, formed by applying the plaster base on a support), whereby the patch is directly adhered to the skin. It is easy to use and easy to use.
- a sheet-like hydrous plaster is conventionally prepared from a plaster base containing gelatin and Z or a water-soluble polymer such as polyacrylic acid or polyacrylate in order to increase the water content in the plaster. Had been formed.
- a plaster base containing gelatin can form a plaster having a high water content and excellent shape retention and cohesiveness, is excellent in use feeling such as moist feeling, and has a plaster. It is possible to form a sheet-like hydrogel with reduced remaining problems. Also disclosed is a poultice having a sheet-like hydrous plaster formed from a plaster base obtained by further mixing agar with a gelatin-based base with the intention of further improving the water content and shape retention. (See Patent Document 1).
- Patent Document 1 JP-A-57-42617
- gelatin may not be blended so that the components that can be added are not limited by the pH of the plaster base.
- the plaster In a conventional plaster base not containing gelatin, the plaster has a sufficient water content. It cannot be used, and the feeling of use such as a feeling of moisture is reduced.
- the water content of a conventional paste base containing no gelatin is increased, there is a problem in that the formed paste strength is oozing out of water and the stickiness of the paste is insufficient. On the other hand, if it is attempted to suppress the exudation of water, the plaster becomes too sticky or sticky.
- the present invention has been made in view of the above-mentioned problems of the related art, and it has been found that even a composition containing a desired component and having a desired pH can sufficiently provide a feeling of use such as a moist feeling.
- Another object of the present invention is to provide a patch in which oozing of water from the plaster is sufficiently reduced and which has a sufficient adhesive strength.
- a sheet-like plaster formed from a plaster base containing 70% by mass or more of moisture has a sufficiently excellent moist feeling.
- a plaster having a sufficient water content can be formed into a sheet without containing gelatin, and
- the present inventors have found that the sheet-like plaster has excellent shape-retaining properties and adhesive strength, and has sufficiently reduced the bleeding of water, thereby completing the present invention.
- the patch of the present invention is a patch comprising a support, and a sheet-like water-containing plaster composed of a plaster base disposed on at least one surface of the support, the plaster base comprising
- (a) contains substantially no gelatin
- (b) contains 70% by mass or more of water
- (c) contains 3.0% to 10% by mass of a water-soluble polymer
- (d) ) Xanthan gum and / or polyvinylpyrrolidone are contained in a total amount of 0.01% by mass to 1.4% by mass.
- the patch of the present invention includes a water-containing plaster formed by forming a plaster base having the above characteristics in a sheet shape.
- substantially free of gelatin means that no gelatin is contained, It means that the amount thereof does not affect the jelly strength of the pressure-sensitive adhesive layer formed from the pressure-sensitive adhesive base.
- a force affecting the jelly strength of the pressure-sensitive adhesive layer can be determined by the following method. That is, the jelly strength of the pressure-sensitive adhesive layer formed from a certain amount of gelatin contained in the pressure-sensitive adhesive base is larger or changed with respect to the jelly strength of the pressure-sensitive adhesive layer formed from the certain pressure-sensitive adhesive base. In that case, it is determined that the jelly strength of the pressure-sensitive adhesive layer is not affected, and a certain amount of gelatin can be regarded as “substantially free of gelatin”. When comparing the jelly strength, the difference shall be confirmed taking into account the measurement error.
- Jelly strength refers to a gel prepared by preparing a 1.5% by mass solution of agar, leaving it at 20 ° C for 15 hours, and coagulating the gel for 20 seconds per square centimeter of its surface. Jelly strength (g / cm 2 ) is defined as the maximum weight (g number) that can be withstood.
- the patch of the present invention is provided with a sheet-like water-containing plaster formed from a plaster base satisfying the above-mentioned conditions (a) to (d), and is sufficiently excellent in usability such as moist feeling.
- the exudation of water from the plaster is sufficiently reduced, and the adhesive has sufficient adhesive strength.
- the patch of the present invention solves the above-mentioned problems caused by gelatin by substantially not containing the above-mentioned condition (a) gelatin. That is, in the case of a paste containing gelatin, it is possible to select a formulation (component composition, pH) that does not sufficiently satisfy the shape retention, cohesiveness and adhesiveness of the paste. Further, the problem of sagging of the plaster observed when using a conventional cataplasm containing gelatin is sufficiently reduced. This is because, when the temperature of the outside air becomes high, for example, 30 ° C. or more, the state of gelatin changes and the cohesive force of the plaster decreases, and it can be prevented by substantially not including gelatin.
- a formulation component composition, pH
- the patch of the present invention provides a sheet-like hydrous plaster formed from a plaster base that satisfies all of the above-mentioned conditions (a) to (d), and The dispensing is sufficiently suppressed, and the feeling of use and adhesiveness can be satisfied at a high level. Simultaneously satisfying these characteristics can solve the problem of moisturizing and safety, especially in applications such as sticking to the face.
- the patch of the present invention has an effect that, when the plaster base satisfies the above conditions (a) to (d), the production time of the patch is shorter than before.
- the water-soluble polymer in the plaster must be sufficiently bridged. That is, a predetermined time was required after the plaster base was applied on the support until the water-soluble polymer was sufficiently crosslinked. Usually, this time was 13 to 18 days at room temperature for a patch provided with a conventional sheet-like hydrogel using gelatin or polyacrylic acid or the like.
- a plaster base satisfying the above conditions (a) to (d) can form a sheet-like hydrous plaster in a shorter time than before.
- the patch of the present invention can reduce the time (lead time) until it is shipped as a product as compared with a patch having a conventional sheet-like hydrogel, and is excellent in productivity. .
- the plaster base further contains easily soluble agar as a water-soluble polymer.
- the "soluble agar” means agar that is almost 100% soluble at a temperature of 70 ° C.
- the composition, molecular weight, morphology, jelly strength, sol viscosity, freezing point, pH, water absorption, syneresis and the like of the agar are not particularly limited as long as they have a powerful property.
- the plaster base preferably contains, as a water-soluble polymer, easily soluble agar, polyacrylic acid, Z or a salt thereof.
- the plaster base is sufficiently excellent in usability such as moistness.
- the thickness of the sheet-like water-containing gypsum body included in the patch of the present invention can be appropriately set according to the application.
- the thickness of the plaster is preferably 1.0 to 1.6 mm.
- the composition contains a desired component and has a desired pH, it is sufficiently excellent in usability such as hydration and the like, and oozing of water from the plaster is sufficiently reduced.
- a patch having sufficient adhesive strength can be provided.
- FIG. 1 is a perspective view showing a preferred embodiment of the patch of the present invention.
- FIG. 1 is a perspective view showing a preferred embodiment of the patch of the present invention.
- a patch 1 comprises a support 2, a sheet-like hydrous body 3 laminated on the support 2, and a release sheet 4 adhered to the sheet-like hydrous body 3. It is.
- the sheet-shaped hydrogel 3 included in the patch 1 of the present embodiment is formed from a plaster base that requires the following conditions.
- the plaster base contains (a) substantially no gelatin, and (b) contains 70 mass% of water.
- the water-containing gypsum sheet 3 formed from a plaster base satisfying the above conditions may contain a desired component and have a desired pH (particularly, pH 4 to 7).
- a desired component particularly, pH 4 to 7
- the exudation of water in the plaster strength is sufficiently reduced, and the adhesive has sufficient adhesive strength.
- the patch 1 of the present embodiment is provided with the sheet-shaped hydroplasty body 3, thereby being excellent in convenience, handling, and handling when used.
- Purified water, sterilized water, natural water, or the like can be used as the water mixed with the plaster base.
- Such water acts as a dispersant for the water-soluble polymer and other components. It is. Water itself also has effects such as significantly improving the feeling of use during and after use.
- the plaster base used in the present embodiment needs to have a water content of 70% by mass or more. If the water content is less than 70% by mass, a sufficient moist feeling cannot be obtained. In the present embodiment, it is preferable that the water content of the plaster base is 75 to 85% by mass. If the water content is less than 75% by mass, the feeling of cooling and coolness tends to decrease, while if it exceeds 85% by mass, it tends to be difficult to maintain shape retention.
- water-soluble polymer examples include a natural polymer, a cellulose-based polymer, an acrylic polymer, and a vinyl-based polymer.
- Examples of natural polymers include agar such as readily soluble agar, agarose, sodium alginate, ammonium alginate, gum arabic, carrageenan, guar gum, locust bean gum, pectin, tragacanth, starch, soluble starch, 13-glucan, pullulan, xanthan gum, dextrin, casein and the like.
- Examples of cellulosic polymers include etyl cenorellose, canoleboxy methinoresenolerose, canolevoxy methinoresenolerose sodium, hydroxymethinoresenolerose, hydroxyethinoresenorelose, hydroxypropinoresenorelose, and hydroxy.
- acrylic polymer include polyacrylic acid, polyacrylate, sodium polyacrylate, carboxybutyl polymer, polyacrylamide, polyacrylamide-acrylate copolymer, and methacrylic acid polymer.
- vinyl polymer include polyvinylpyrrolidone, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpyrrolidone vinyl alcohol copolymer, polyvinyl ether, methoxyethylene maleic anhydride copolymer, and isobutylene maleic anhydride copolymer.
- Examples thereof include polymers, N-vinylacetamide, and copolymers of N-butylacetamide with acrylic acid and Z or acrylate.
- Other examples include carboxymethyl amylose and polyethylene oxide. These can be used alone or in combination of two or more.
- xanthan gum and Z or polyvinylpyrrolidone are mixed with the plaster base in a total amount of 0.01% by mass to 1.4% by mass. You If the total amount of the water-soluble polymer to be blended is 3.0% by mass to 10% by mass in the paste base, the type and amount of the water-soluble polymer used in addition to xanthan gum and polybutylpyrrolidone It is not particularly limited.
- the water-soluble polymer preferably contains easily soluble agar and polyacrylic acid and Z or a salt thereof!
- the jelly strength is more preferably agar preferred instrument 500 ⁇ 800GZcm 2 force 390 ⁇ 1200gZcm 2, 650 ⁇ 750g / cm 2 is not particularly preferred. If the jelly strength of the easily soluble agar is less than 390 gZcm 2 , the shape retention tends to decrease. On the other hand, when the jelly strength exceeds 1200 gZcm 2 , the plaster becomes hard and brittle.
- the easily soluble agar preferably contains almost no agaropectin, and is preferably agar.
- Agaropectin contains a large amount of ionic functional groups and has almost gelling ability.
- the easily soluble agar containing almost no agaropectin is preferable because it can efficiently perform gelling with a smaller amount of compounding and can be more easily dissolved.
- known ones can be used, and commercially available ones include, for example, “UP-37K”, manufactured by Ina Food Industry Co., Ltd. jelly strength: 700g / cm 2), “UP- 26K”, Ina Food Industry Co., Ltd., jelly strength: 650g / cm 2), “UP- 16K”, Ina Food Industry Co., Ltd., jelly strength: 600g / cm 2), “UZ-5K”, manufactured by Ina Food Industry Co., Ltd., jelly strength: 420 g / cm 2 ), “UM-11 K”, manufactured by Ina Food Industry Co., Ltd., jelly strength: 1000 g / cm 2 ) Can be
- the total of the easily soluble agar and polyacrylic acid and Z or a salt thereof is 3 to 8% by mass in the paste base. Is preferred. If the above total is less than 3% by mass, the plaster tends to be soft, and if it exceeds 8% by mass, the plaster tends to be hard.
- the mass of the easily soluble agar and the sum of polyacrylic acid and Z or a salt thereof is 1: 8 to 1:16. If the proportion of readily soluble agar is less than 1Z16, the shape retention tends to decrease, and if it exceeds 1Z8, the plaster tends to be hard and brittle.
- the plaster base used in the present embodiment includes, in addition to water and the water-soluble polymer, Accordingly, a medicinal component, a cosmetic component, and various components that can be generally blended into a plaster may be contained.
- a medicinal component e.g., a cortisol, a hydroxyanisole, a hydroxyanisole, a hydroxyanisole, a hydroxyanisole, a hydroxyanisole, a hydroxyanisole, and various components that can be generally blended into a plaster may be contained.
- the components that can be generally blended into the plaster include polyhydric alcohols, polyvalent metal salts, and surfactants.
- Pharmaceutical ingredients include anti-inflammatory analgesics such as indomethacin, ketoprofen, flurbiprofen, fernavik, ketorolata, diclofenac sodium; anti-emetic agents such as dara-setron hydrochloride, azasetron hydrochloride, ondansetron hydrochloride, ramosetron hydrochloride; estradiol, Estrone, estriol, equilin, echirenine, and their derivatives, progesterone, hydroxyprogesterone dyprosate, hydroxyprogesterone acetate, dydrogesterone acetate, chlormadinone acetate, ethisterone, dimethylesterone, norethisterone, norethisterone acetate, norletosterone enanthate, ethendiol acetate Hormonal agents such as megestrol acetate and allylestrenol; therapeutic agents for pollakiuria
- Bold Drugs such as diuretics such as hydroflumethiazide; diabetic agents such as tributamide; ventilation agents such as colchicine; antiparkinson agents such as amantadine and levodopa; and anti-vertigo agents such as diphen-dol and betahistine. .
- diuretics such as hydroflumethiazide
- diabetic agents such as tributamide
- ventilation agents such as colchicine
- antiparkinson agents such as amantadine and levodopa
- anti-vertigo agents such as diphen-dol and betahistine.
- the amount of the above-mentioned medicinal component is preferably 0.01 to 10% by mass in the plaster base, although it depends on the drug used and the use.
- the amount is preferably 0.05 to 0.5% by mass in the plaster base, and 0.1 to 0.4% by mass is preferred. Is more preferred. If the amount of placenta extract is less than 0.05% by mass, the effect tends to be difficult to obtain, while if it exceeds 0.5% by mass, the amount tends to be excessive for the required effect. .
- Cosmetic components include allantoin, ascorbic acid, ascorbic acid derivatives, malonie extract, water-soluble placenta extract, sage extract, kojic acid, lecithin, amino acids, hormones, placenta extract, vitamin A, vitamin D, Examples include vitamin E and their derivatives, dipotassium glycyrrhizinate, caffeic acid, and fruit juice extracts.
- the paste base used in the present embodiment incorporates the above-mentioned readily soluble agar, a high temperature (about 90 ° C. or higher) for dissolving the agar is not required, so that the loss during production is A volatile or thermally decomposable component having a large particle size can be suitably blended.
- any component that can be volatilized by applying heat for example, heat of about 90 ° C or more
- heat for example, heat of about 90 ° C or more
- Flavoring agents drugs such as amyl nitrite and trimetadione and cosmetics, C8-C22 fatty acids such as isostearic acid, octanoic acid, and oleic acid; C8-C22 fatty alcohols such as oleyl alcohol and lauryl alcohol; Ethyl oleate, isopropyl myristate, butyl stearate, and methyl laurate
- ethers of fatty acids C8-C22 dialkyl esters of C6 ⁇ C8 diacid diisopropyl adipate, fatty acid monoglycerides C8-C22, such as glyceryl monolaurate, tetrahydrofurfuryl alcohol
- Liquid polyethylene excipients such as polyethylene glycol glycol ether, polyethylene glycol, propylene glycol, 21- (2-ethoxyethoxy) ethanol, diethylene glycol monomethyl ether, and mixtures thereof.
- the amount of these components is 0.005-5.
- menthol is more preferably 0% by mass, more preferably 0.01% to 2.0% by mass. If the blending ratio of menthol is less than 0.005% by mass, the medicinal effect of menthol tends to be obtained, while if it exceeds 5.0% by mass, menthol is likely to exude from the plaster. It's in the way.
- the thermally decomposable component may be any substance that is unstable to heat (eg, heat of about 90 ° C or higher).
- non-functional compounds having a carboxylic acid group such as diclofenac, fuerbinac, indomethacin, and ketoprofen may be used.
- Steroidal anti-inflammatory drugs prostaglandins, proteins such as albumin, toxins such as diphtheria toxin, enzymes such as catalase, cyclosporine 8, hirudin, somatostatin, peptides such as thymopentin, hormones such as estrogen, human growth hormone, Peptide hormones such as porcine growth hormone, pest growth hormone, human calcitonin, salmon calcitonin, carboxylucitonin and insulin, hormone antagonists, neurotransmitters such as acetylcholine, neurotransmitters antagonists, hyaluronic acid, etc.
- Glycoprotein (X-lipoprotein Lipoproteins, immunoglobulins such as IgG, immunomodulators such as interferon and interleukin, cellular receptors such as estrogen receptor protein, unfractionated heparin, low-molecular-weight heparin, chondroitin 4-sulfate, chondroitin Tin 6-sulfuric acid, glycosaminodalicans such as derivatives thereof, plant extracts such as prostaglandins, ginseng, al-force, kinsen-force, yeasts such as selenium yeast, brewer's yeast, ovalbumin, gelatin, etc.
- immunoglobulins such as IgG
- immunomodulators such as interferon and interleukin
- cellular receptors such as estrogen receptor protein
- unfractionated heparin unfractionated heparin
- low-molecular-weight heparin chondroitin 4-sulfate
- chondroitin Tin 6-sulfuric acid glycosaminodalican
- Animal proteins such as dalten, hydrolyzed collagen, hydrolysates of animal or vegetable proteins such as hydrolyzed wheat dartene, natural polysaccharides such as hyaluronic acid, lecithin, collagen, placenta kiss, Ascorbic acid and its esters, retinol and its esters, vitamin A Oils, vitamins such as hydroxocobalamin acetate, ergocalcifenol, isosorbide dinitrate, nitroglycerin, testosterone enanthate, ergotamine tartrate, pergolide, -cotin, aluminum nitrite, ethichlorbinol, paramethadione, scopolamine, etc.
- vitamins such as hydroxocobalamin acetate, ergocalcifenol, isosorbide dinitrate, nitroglycerin, testosterone enanthate, ergotamine tartrate, pergolide, -cotin, aluminum nitrite, ethichlorbinol, paramethadione
- the compounding amount is preferably 0.01 to 5.0% by mass in the plaster base, and is 0.1 to 1.0% by mass. Is more preferable. If the mixing ratio of ketoprofen is less than 0.01% by mass, the medicinal effect of ketoprofen tends to be difficult to obtain, while if it exceeds 5.0% by mass, the compounding amount is excessive with respect to the desired medicinal effect. It tends to be.
- polyhydric alcohol examples include glycerin, polyethylene glycol, 1,3-butylene glycol, propylene glycol, dipropylene glycol, sorbitol, and xylitol.
- glycerin is particularly preferred in that it has good workability and usability.
- the blending amount of the polyhydric alcohol in the paste base is preferably 5 to 15% by mass, more preferably 8 to 12% by mass. If the blending ratio is less than 5% by mass, the plaster tends to be hard, while if it exceeds 12% by mass, the oozing of water from the plaster tends to occur.
- polyvalent metal salt examples include aluminum hydroxide, aluminum hydroxide gel, hydrated aluminum silicate, synthetic aluminum silicate, kaolin, aluminum acetate, aluminum lactate, aluminum stearate, and calcium chloride.
- the compounding amount of the polyvalent metal salt is preferably 0.01 to 1% by mass, more preferably 0.02 to 0.5% by mass, in the paste base. If the compounding ratio is less than 0.01% by mass, the reaction does not proceed sufficiently and the gel strength tends to be insufficient. On the other hand, if it exceeds 1% by mass, the reaction rate during production is too fast. There is a tendency for the gelling to be uneven and the workability to be reduced, or the adhesiveness of the plaster to be insufficient.
- surfactant examples include sodium octyl sulfosuccinate, alkyl sulfate salt, 2-ethylhexyl alkyl sulfate sodium salt, and normal dodecyl ester.
- Anionic surfactants such as sodium benzenesulfonate; cationic surfactants such as hexadecyltrimethylammonium-dimethyl chloride, octadecyldimethylbenzylammonium-dimethyl chloride, polyoxyethylene dodecyl monomethylammonium-dimethyl chloride; polyoxyethylene Polyoxyethylene monostearate, sorbitan monostearate, sorbitan monostearate, such as stearyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene tridecyl ether, polyoxyethylene nonyl phenyl ether, polyoxyethylene octyl phenyl ether, and polyethylene glycol monostearate Palmitate, sorbitan sesquioleate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan Examples include nonionic surfactants such as nooleate, glycerol monostearate, polyglycerin fatty acid este
- the blending amount of the surfactant is preferably from 0.01 to 5% by mass, more preferably from 0.1 to 2% by mass in the plaster base. If the blending ratio is less than 0.01% by mass, pread tends to occur, while if it exceeds 5% by mass, it tends to be difficult to maintain the shape retention.
- the plaster base used in the present embodiment may include, if necessary, a skin-skinning component, a moisturizing component, an antioxidant, a cross-linking agent, a preservative, a tackifier, a dissolving agent, a pigment, a fragrance, an ultraviolet ray. It is also possible to incorporate an absorbent, an inorganic filler, a pH adjuster, and the like.
- Examples of the beautiful skin component include aloe extract, age extract, orange extract, raspberry extract, kiwi extract, cucumber extract, gardenia extract, potato beetle extract, hawthorn extract, sycamore extract, taiso extract, duke extract, and tomato extract.
- These can be used alone or in combination of two or more.
- crude drug components such as red bean, katsukon, shatayaku, touki, senkiyu, chiyouji, assembly, soujiyuu, chimpi, biyakuju, spruce, keihi, orelen, obatta, ichiyou, etc., bentonite, montmorillonite, sabonite, Examples include mud components such as hectorite.
- Examples of the moisturizing component include an aqueous solution of acylated kefuirane, malt extract, urea, and glycols. These can be used alone or in combination of two or more.
- Antioxidants include, for example, ascorbic acid, propyl gallate, butylhydroxylanol, dibutylhydroxytoluene, nordihydroguaiaretinic acid, tocopherol, tocopherol acetate, natural vitamin E, sodium nitrite, And sodium hydrogen nitrite.
- crosslinking agent examples include thermosetting resins such as hardly water-soluble aluminum compounds, polyfunctional epoxy compounds, amino resins, phenol resins, epoxy resins, alkyd resins, and unsaturated polyesters, and isocyanate resins.
- thermosetting resins such as hardly water-soluble aluminum compounds, polyfunctional epoxy compounds, amino resins, phenol resins, epoxy resins, alkyd resins, and unsaturated polyesters, and isocyanate resins.
- Compounds, block isocyanate conjugates, organic crosslinking agents, and inorganic crosslinking agents such as metals or metal compounds. These can be used alone or in combination of two or more.
- Examples of the preservatives include ethyl ethyl noraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, sorbic acid, dehydroacetic acid, and the like.
- tackifier examples include casein, pullulan, dextran, sodium alginate, soluble starch, carboxystarch, dextrin, carboxymethylcellulose, canoleboxy methinoresenorelose sodium, methinoresenorelose, etinoresenorelose.
- Hydroxyethyl cellulose polyvinyl alcohol, polyethylene oxide, polyatarylamide, polyacrylic acid, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, polymaleic acid copolymer, methoxyethylene maleic anhydride copolymer, isobutylene anhydride Maleic acid copolymer, polyethyleneimine, polyvinyl alcohol part Kenyidani, hydroxypropyl methylcellulose, xanthan gum, N-butyl acetate Etc. The.
- solubilizer examples include getyl sebacate, N-methyl-2-pyrrolidone, and salici.
- examples include methyl luate, glycol salicylate, triacetin, oleyl alcohol, benzyl alcohol, isopropyl myristate, diisopropyl adipate, crotamiton, potato oil, camellia oil, castor oil, and olive oil.
- Examples of the dye include Red No. 2 (Amaranth), Red No. 3 (Eris Mouth Shin), Red No. 102
- fragrance examples include heart oil, keich oil, cinnamon oil, fennel oil, castor oil, turpentine oil, eucalyptus oil, orange oil, lavender oil, lemon oil, rose oil, lemongrass oil and the like. And plant extracts such as marie and sage.
- Examples of the ultraviolet absorber include, for example, paraaminobenzoic acid, paraaminobenzoic acid ester, paradimethylaminobenzoic acid amyl, salicylate, menthyl anthralate, pumbelliferone, esculin, benzyl cinnamate, sinoxate, guaiazulene, Perocanic acid, 2- (2-hydroxy-15-methylphenyl) benzotriazole, 4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone, dioxybenzone, octabenzone, dihydroxydimethoxybenzophenone, slisobenzone Benzoresorcinol, octyldimethylparaaminobenzoate, ethylhexylparamethoxycinnamate, and butylmethoxydibenzoylmethane.
- paraaminobenzoic acid paraaminobenzoic acid ester
- Examples of the inorganic filler include calcium carbonate, magnesium carbonate, silicates (eg, aluminum silicate, magnesium silicate, and the like), citric acid, barium sulfate, calcium sulfate, calcium zincate, and zinc oxide. And titanium oxide.
- silicates eg, aluminum silicate, magnesium silicate, and the like
- citric acid barium sulfate, calcium sulfate, calcium zincate, and zinc oxide.
- titanium oxide titanium oxide.
- Examples of the pH adjuster include acetic acid, formic acid, lactic acid, tartaric acid, oxalic acid, benzoic acid, dalicholic acid, malic acid, citric acid, hydrochloric acid, nitric acid, sulfuric acid, sodium hydroxide, calcium hydroxide, Methylamine, ethylamine, propylamine, dimethylamine, getylamine, dipyramine, trimethylamine, triethylamine, tripropylamine, monomethanolamine, monoethanolamine, monopropanolamine, dimethanolamine, diethanolamine , Dipropanolamine, trimethanolamine, triethanolamine, tripropanol Lumin, citrate buffer, phosphate buffer, glycine buffer, acetate buffer and other buffers.
- the sheet-shaped hydrogel 3 formed from the plaster base containing the above-described components is disposed on the support 2.
- the support 2 used for the patch 1 of the present embodiment is not particularly limited as long as it can support the sheet-like hydrogel 3, and a stretchable or non-stretchable support can be used. .
- Examples of the support 2 include polyurethane, polyester, polypropylene, poly (vinyl acetate), polyvinylidene chloride, polyethylene, polyethylene terephthalate, aluminum sheet, nylon, acrylic, cotton, rayon, and acetate. And the like. Synthetic fibers or natural fibers such as those described above, or a fiber sheet formed by combining these fibers into a woven or nonwoven fabric, and a fiber sheet which is a composite material of these and a film having water vapor permeability.
- a woven or nonwoven fiber sheet made of polyethylene terephthalate which is preferably a woven or nonwoven fiber sheet made of polyester, polyethylene, or polyethylene terephthalate in terms of safety, versatility, and stretchability Is more preferred,.
- a fiber sheet has flexibility, even if it is thick, and follows the skin and has low skin irritation immediately. Furthermore, by using such a fiber sheet, it is possible to obtain a patch having an appropriate self-supporting property.
- the moisture of the plaster can be suppressed from evaporating, so that the feeling of moisture is further improved.
- the adhesive preparation 1 includes a release sheet 4 adhered on the sheet-like hydrogel body 3.
- a release sheet 4 include polyester such as polyethylene terephthalate, films such as polychloride butyl, polychloride violetidene, and laminating film of high quality paper and polyolefin. These release sheets are preferably subjected to silicone treatment on the surface in contact with the sheet-shaped hydrogel body 3 because the workability when the release sheet 4 is released from the patch 1 is improved.
- a plaster base is prepared by adding each component such as a water-soluble polymer and a medicinal ingredient to purified water and stirring and mixing these components.
- component such as a water-soluble polymer and a medicinal ingredient
- purified water For stirring conditions, etc., It may be set appropriately according to the type of the soluble polymer.For example, when easily soluble agar is used, the agar is added to purified water at 65 to 85 ° C and stirred for 5 to 15 minutes to reduce the agar. In minutes to prepare a plaster base.
- the obtained plaster base is applied on a support to form a coating film, and a release sheet is laminated on the coating film.
- This is stored at room temperature for several days, and the water-soluble polymer is sufficiently crosslinked to form a sheet-like hydrogel.
- the thickness of the formed hydrogel sheet is in the range of 0.8 to 1.6 mm. If the film thickness is less than 0.8 mm, the film thickness is too thin, so that sufficient adhesive strength tends not to be obtained. If the film thickness is more than 1.6 mm, the film thickness is too thin, and the film tends to peel off during use. There is a tendency.
- the patch is obtained by cutting it into a predetermined shape.
- the water-soluble polymer in the preparation of the plaster base, as the water-soluble polymer, easily soluble agar, and polyacrylic acid and Z or a salt thereof are contained. preferable.
- the easily soluble agar does not require a high temperature (90 ° C. or higher) for dissolution, the volatile or thermally decomposable component described above can be efficiently incorporated into the patch.
- it is possible to simplify the manufacturing process which requires an apparatus for cooling the solution of agar, energy, time and the like in order to mix volatile or thermally decomposable components.
- the content ratio of each component in the formed sheet-like hydrogel is determined according to the above range. It is easy to put in, and it has a sufficiently excellent usability such as moistness, and has sufficiently reduced oozing of water from the plaster, and has a sufficient adhesive strength to produce a patch. It is possible to get it.
- the patch may have a circular or elliptical shape. Also, holes or cuts may be provided. Further, the shape can be appropriately designed according to the body part where the patch is used. For example, cut it into a facial shape so that it can be attached to the face, , Nose, mouth and chin cut into appropriate shapes.
- a paste base is applied onto a release sheet to form a sheet-like hydrous body, and then the support is laminated to the sheet-like hydrous body.
- the patch of the present invention can be used as a pharmaceutical or a poultice similar thereto, a cooling sheet, a cosmetic or a similar pack, and the like.
- Table 1 shows the components and mixing ratios of the prepared plaster bases. The values in Table 1 are expressed in mass%.
- the pH of the plaster base was 6.4.
- the obtained plaster base was spread on a cloth (25 cm x 25 cm) manufactured by Nippon Vileen Co., Ltd. as a support so as to have a thickness of 1.4 mm. Formed. Further, a product obtained by attaching a release film to the coating film was stored at room temperature to form a sheet-like hydrogel, thereby obtaining a patch which can be shipped as a product.
- the criteria for the patch to be ready for shipment are as follows.
- a plaster base was prepared in the same manner as in Example 1 except that the component compositions shown in Table 1 were used.
- the pH of the plaster base was 6.3 to 6.5.
- Example 1 Using the obtained plaster base, a patch was obtained in the same manner as in Example 1. Table 1 shows the number of days (lead time) from the start of preparation of the plaster base to the point where it can be shipped. Further, the obtained patch was evaluated in the same manner as in Example 1. The results are shown in Table 1.
- a patch was obtained in the same manner as in Example 1 except that gelatin was used in the preparation of the plaster base and the component composition was as shown in Table 2.
- Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Comparative Example 7 Gelatin 1.0 1.2 1 0----Polyacrylic acid------1.5-Polyacrylic acid Na 6.0 3.0 9.0 7.0 1. 0 4.0 10.0 Xanthan gum--0.5-0.5--Polyvinyl 1.1 1.5 1.1 Pyrrolidone
- Example 2 In preparing the plaster base, the same as in Example 1 except that the component compositions shown in Table 2 were used. To give a patch.
- the patches of Examples 1 to 4 had a lead time of 8 to 11 days, whereas the patches of Comparative Examples 4, 6 and 7 had a lead time of 14 to 16 days. From these facts, it was a component that the patches of Examples 1 to 4 were excellent in productivity.
- a composition containing a desired component and having a desired pH is sufficiently excellent in usability such as moist feeling and sufficiently reduces oozing of moisture from the plaster.
- a patch having sufficient adhesive strength can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
明 細 書 Specification
貼付剤 Patch
技術分野 Technical field
[0001] 本発明は、貼付剤に関する。 The present invention relates to a patch.
背景技術 Background art
[0002] 医薬品として用いられるノップ剤、化粧品又は医薬部外品として用いられるノック 剤等の貼付剤はシート状含水膏体を備えている。シート状含水膏体は、膏体基剤を シート状に形成 (例えば、膏体基剤を支持体上に塗布することにより形成)したもので あるが、これにより、貼付剤は皮膚にそのまま貼付して使用できる等の利便性や取り 扱い性に優れたものとなっている。このようなシート状含水膏体は、膏体中に水分を 高含有させるために、従来、ゼラチン及び Z又はポリアクリル酸、ポリアクリル酸塩等 の水溶性高分子を配合した膏体基剤から形成されていた。 [0002] Patches such as knocking agents used as pharmaceuticals, knocking agents used as cosmetics or quasi-drugs, etc. are provided with sheet-like hydrogel bodies. In the sheet-like hydrous plaster, the plaster base is formed into a sheet (for example, formed by applying the plaster base on a support), whereby the patch is directly adhered to the skin. It is easy to use and easy to use. Such a sheet-like hydrous plaster is conventionally prepared from a plaster base containing gelatin and Z or a water-soluble polymer such as polyacrylic acid or polyacrylate in order to increase the water content in the plaster. Had been formed.
[0003] 特に、ゼラチンを含有する膏体基剤は、高い水分含量を有すると共に保型性及び 凝集性に優れた膏体を形成することができ、潤い感などの使用感に優れ、膏体残り 等の問題が低減されたシート状含水膏体を形成することができる。また、水分含量及 び保型性をさらに向上させることを意図して、ゼラチンベースの基剤に寒天をさらに 配合させた膏体基剤から形成されたシート状含水膏体を備えるパップ剤も開示され ている (特許文献 1参照。)。 [0003] In particular, a plaster base containing gelatin can form a plaster having a high water content and excellent shape retention and cohesiveness, is excellent in use feeling such as moist feeling, and has a plaster. It is possible to form a sheet-like hydrogel with reduced remaining problems. Also disclosed is a poultice having a sheet-like hydrous plaster formed from a plaster base obtained by further mixing agar with a gelatin-based base with the intention of further improving the water content and shape retention. (See Patent Document 1).
特許文献 1 :特開昭 57— 42617号公報 Patent Document 1: JP-A-57-42617
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0004] し力しながら、特許文献 1に記載のノ ップ剤をはじめとするゼラチンを含有する従来 の貼付剤では、ゼラチン以外の配合物質 (例えば薬効成分等)の選択範囲が膏体基 剤の pHによって制限されることがあった。これは、膏体基剤の PHが、ゼラチンの保 型力、凝集力等が十分に発揮され得る所定の pHの範囲から外れた場合、形成され る膏体の保型性、凝集性、粘着性等が低下するという問題が生じるためである。特に 、膏体基剤から膏体をシート状に形成した場合、膏体からの水分の滲み出しが顕著 となる。そのため、上記従来の貼付剤は、貼付剤の設計上の自由度において十分な ものとはいえなかった。 [0004] In the past, in conventional patches containing gelatin, such as the napping agent described in Patent Document 1, the selection range of compounding substances other than gelatin (for example, a medicinal ingredient) is based on plaster base. Sometimes limited by the pH of the agent. This, P H of the plaster base is, shape-retaining force of gelatin, when deviated from a predetermined range of pH of cohesion or the like can be sufficiently exhibited, shape retention plaster that will be formed, cohesive, This is because a problem that the adhesiveness or the like is reduced occurs. In particular, when the plaster is formed into a sheet from the plaster base, the seepage of moisture from the plaster is remarkable. It becomes. Therefore, the conventional patches described above were not sufficient in the degree of freedom in designing the patches.
[0005] なお、膏体基剤の pHによって添加できる成分が制限されないようにゼラチンを配合 させないことが考えられる力 従来のゼラチンを配合しない膏体基剤では、膏体が十 分な水分含量を有することができず、潤い感などの使用感が低下してしまう。また、従 来のゼラチンを配合しない膏体基剤は、水分含量を大きくしていくと、形成される膏 体力も水分が滲み出したり、膏体の粘着性が不足したりする問題が生じる。一方、水 分の滲み出しを抑制しょうとすると、粘着力が強すぎたり、膏体のべたつきが生じたり する膏体となってしまう。 [0005] It is considered that gelatin may not be blended so that the components that can be added are not limited by the pH of the plaster base. In a conventional plaster base not containing gelatin, the plaster has a sufficient water content. It cannot be used, and the feeling of use such as a feeling of moisture is reduced. In addition, when the water content of a conventional paste base containing no gelatin is increased, there is a problem in that the formed paste strength is oozing out of water and the stickiness of the paste is insufficient. On the other hand, if it is attempted to suppress the exudation of water, the plaster becomes too sticky or sticky.
[0006] 本発明は、上記従来技術の有する課題に鑑みてなされたものであり、所望の成分 を含有し所望の pHを有する配合であっても、潤 ヽ感などの使用感に十分優れると共 に、膏体からの水分の滲み出しが十分に低減されており、かつ十分な粘着力を有す る貼付剤を提供することにある。 [0006] The present invention has been made in view of the above-mentioned problems of the related art, and it has been found that even a composition containing a desired component and having a desired pH can sufficiently provide a feeling of use such as a moist feeling. Another object of the present invention is to provide a patch in which oozing of water from the plaster is sufficiently reduced and which has a sufficient adhesive strength.
課題を解決するための手段 Means for solving the problem
[0007] 本発明者らは、上記目的を達成すべく鋭意研究を重ねた結果、水分を 70質量% 以上含有する膏体基剤から形成されるシート状の膏体が十分に優れた潤い感を有し ていること、及び、膏体基剤を特定の組成とすることにより、ゼラチンを含有させること なく十分な含水量を有する膏体をシート状に形成することができ、かつ形成されたシ ート状の膏体が保型性、粘着力に優れ、水分の滲み出しが十分に低減されているこ とを見出し、本発明を完成するに至った。 [0007] The inventors of the present invention have conducted intensive studies to achieve the above object, and as a result, a sheet-like plaster formed from a plaster base containing 70% by mass or more of moisture has a sufficiently excellent moist feeling. By having a specific composition of the plaster base, a plaster having a sufficient water content can be formed into a sheet without containing gelatin, and The present inventors have found that the sheet-like plaster has excellent shape-retaining properties and adhesive strength, and has sufficiently reduced the bleeding of water, thereby completing the present invention.
[0008] 本発明の貼付剤は、支持体と、この支持体の少なくとも一方の面上に配置され膏体 基剤からなるシート状含水膏体とを備える貼付剤であって、膏体基剤が、(a)ゼラチ ンを実質的に含まず、(b)水分を、 70質量%以上含有し、(c)水溶性高分子を、 3. 0 質量%〜10質量%含有し、(d)キサンタンガム及び/又はポリビニルピロリドンを、合 計で 0. 01質量%〜1. 4質量%含有することを特徴とする。すなわち、本発明の貼 付剤は、上記特徴を有する膏体基剤をシート状に形成した含水膏体を備えるもので ある。 [0008] The patch of the present invention is a patch comprising a support, and a sheet-like water-containing plaster composed of a plaster base disposed on at least one surface of the support, the plaster base comprising However, (a) contains substantially no gelatin, (b) contains 70% by mass or more of water, (c) contains 3.0% to 10% by mass of a water-soluble polymer, and (d) ) Xanthan gum and / or polyvinylpyrrolidone are contained in a total amount of 0.01% by mass to 1.4% by mass. That is, the patch of the present invention includes a water-containing plaster formed by forming a plaster base having the above characteristics in a sheet shape.
[0009] 本発明において、「ゼラチンを実質的に含まない」とは、ゼラチンを含有しないか、 含有しても粘着基剤から形成される粘着剤層のゼリー強度に影響を及ぼさない程度 の量であることを意味する。ここで、粘着剤層のゼリー強度に影響を及ぼす力否かは 、次の方法により判断することができる。すなわち、ある粘着基剤から形成された粘着 剤層のゼリー強度に対して、この粘着基剤にある量のゼラチンを含有させたものから 形成された粘着剤層のゼリー強度が大きくな 、或いは変わらな 、のであれば、粘着 剤層のゼリー強度に影響を及ぼさないと判断し、ある量のゼラチンは「ゼラチンを実 質的に含まない」とみなすことができる。なお、ゼリー強度の比較に際しては、測定誤 差を考慮した上での差を確認するものとする。 [0009] In the present invention, "substantially free of gelatin" means that no gelatin is contained, It means that the amount thereof does not affect the jelly strength of the pressure-sensitive adhesive layer formed from the pressure-sensitive adhesive base. Here, whether or not a force affecting the jelly strength of the pressure-sensitive adhesive layer can be determined by the following method. That is, the jelly strength of the pressure-sensitive adhesive layer formed from a certain amount of gelatin contained in the pressure-sensitive adhesive base is larger or changed with respect to the jelly strength of the pressure-sensitive adhesive layer formed from the certain pressure-sensitive adhesive base. In that case, it is determined that the jelly strength of the pressure-sensitive adhesive layer is not affected, and a certain amount of gelatin can be regarded as “substantially free of gelatin”. When comparing the jelly strength, the difference shall be confirmed taking into account the measurement error.
[0010] また、本発明において、「ゼリー強度」とは、寒天の 1. 5質量%溶液を調製し、 20°C で 15時間放置、凝固せしめたゲルについて、その表面 1平方センチ当たり 20秒間耐 え得る最大重量 (g数)をもってゼリー強度 (g/cm2)とするものである。 [0010] In the present invention, "jelly strength" refers to a gel prepared by preparing a 1.5% by mass solution of agar, leaving it at 20 ° C for 15 hours, and coagulating the gel for 20 seconds per square centimeter of its surface. Jelly strength (g / cm 2 ) is defined as the maximum weight (g number) that can be withstood.
[0011] 本発明の貼付剤は、上記の条件 (a)〜 (d)を満たす膏体基剤から形成されるシート 状含水膏体を備えることにより、潤い感などの使用感に十分優れると共に、膏体から の水分の滲み出しが十分に低減されており、かつ十分な粘着力を有するものとなつ ている。 [0011] The patch of the present invention is provided with a sheet-like water-containing plaster formed from a plaster base satisfying the above-mentioned conditions (a) to (d), and is sufficiently excellent in usability such as moist feeling. In addition, the exudation of water from the plaster is sufficiently reduced, and the adhesive has sufficient adhesive strength.
[0012] 本発明の貼付剤は、上記条件 (a)ゼラチンを実質的に含まないことにより、上記ゼ ラチンに起因する問題点を解消している。すなわち、ゼラチンを含む膏体では膏体の 保型性、凝集性及び粘着性を十分に満足させることができない配合 (成分組成、 pH )を選択することができるようになつている。更には、ゼラチンを配合した従来のパップ 剤の使用時に見られた膏体のダレの問題も十分に低減することができる。これは、外 気の温度が例えば 30°C以上の高温になるとゼラチンの状態が変化して膏体の凝集 力が低下するのを、ゼラチンを実質的に含まないことにより防止できるためである。 [0012] The patch of the present invention solves the above-mentioned problems caused by gelatin by substantially not containing the above-mentioned condition (a) gelatin. That is, in the case of a paste containing gelatin, it is possible to select a formulation (component composition, pH) that does not sufficiently satisfy the shape retention, cohesiveness and adhesiveness of the paste. Further, the problem of sagging of the plaster observed when using a conventional cataplasm containing gelatin is sufficiently reduced. This is because, when the temperature of the outside air becomes high, for example, 30 ° C. or more, the state of gelatin changes and the cohesive force of the plaster decreases, and it can be prevented by substantially not including gelatin.
[0013] 上記条件 (b)にお 、て、水分の含有割合が 70質量%未満であると、シート状含水 膏体は十分な潤 、感を与えることができな 、。 [0013] Under the above condition (b), if the water content is less than 70% by mass, the water-containing gypsum sheet cannot provide sufficient moisture and feeling.
[0014] また、上記条件 (c)にお 、て、水溶性高分子の含有割合が 3. 0質量%未満である と、シート状含水膏体の強度及び保型性が不十分となり、膏体からの水分の滲み出 しを十分に低減することができない。他方、水溶性高分子の含有割合が 10質量%を 超えると、シート状含水膏体が硬くなりすぎて十分な粘着力を得ることができない。 [0015] また、上記条件 (d)にお 、て、キサンタンガム及び Z又はポリビュルピロリドンの含 有割合が合計で 0. 01質量%未満であると、十分な粘着力が得られず、 1. 4質量% を超えると、シート状含水膏体のべたつきが生じて使用感が損なわれる。 [0014] Further, under the above condition (c), if the content of the water-soluble polymer is less than 3.0% by mass, the strength and shape retention of the sheet-like hydrogel body become insufficient, Leaching of water from the body cannot be reduced sufficiently. On the other hand, when the content ratio of the water-soluble polymer exceeds 10% by mass, the sheet-like water-containing plaster becomes too hard to obtain a sufficient adhesive strength. [0015] Also, under the above condition (d), if the total content of xanthan gum and Z or polybutylpyrrolidone is less than 0.01% by mass, sufficient adhesive strength cannot be obtained, and 1. If the content exceeds 4% by mass, the sheet-like hydrogel body becomes sticky and the feeling of use is impaired.
[0016] 一般に、水分含量が 70質量%以上の膏体基剤をシート状に固化すると、保型性が 十分に得られない或いは保型性が経時と共に低下する等の問題があり、形成した膏 体からの水分の滲み出しが十分に抑制されていると共に、使用感及び粘着性を高い 水準で満足することが困難であると考えられる。し力しながら、本発明の貼付剤は、上 記の条件 (a)〜 (d)をすベて満たす膏体基剤から形成されるシート状含水膏体を備 えることにより、水分の滲み出しが十分に抑制されていると共に、使用感及び粘着性 を高い水準で満足できるものとなっている。また、これらの特性を同時に満たすことは 、特に、顔面への貼付等の用途において、保湿及び安全性の課題を解決することが できる。 [0016] In general, when a plaster base having a water content of 70% by mass or more is solidified into a sheet, there is a problem that the shape retention cannot be sufficiently obtained or the shape retention deteriorates with the passage of time. It is considered that the oozing of water from the plaster is sufficiently suppressed, and it is difficult to satisfy a high level of usability and adhesiveness. While applying pressure, the patch of the present invention provides a sheet-like hydrous plaster formed from a plaster base that satisfies all of the above-mentioned conditions (a) to (d), and The dispensing is sufficiently suppressed, and the feeling of use and adhesiveness can be satisfied at a high level. Simultaneously satisfying these characteristics can solve the problem of moisturizing and safety, especially in applications such as sticking to the face.
[0017] 更には、本発明の貼付剤は、膏体基剤が上記条件 (a)〜(d)を満たすことにより、 貼付剤の製造時間が従来よりも短縮されるという効果が得られる。 [0017] Furthermore, the patch of the present invention has an effect that, when the plaster base satisfies the above conditions (a) to (d), the production time of the patch is shorter than before.
[0018] 貼付剤が製品として使用可能となるためには、膏体中の水溶性高分子が十分に架 橋されていなければならない。すなわち、膏体基剤を支持体上に塗布してから水溶 性高分子が十分に架橋されるまでには所定の時間が必要であった。この時間は、通 常、ゼラチン又はポリアクリル酸等を用いた従来のシート状含水膏体を備える貼付剤 では、室温下で、 13〜18日必要であった。一方、上記条件 (a)〜(d)を満たす膏体 基剤は、従来よりも短時間でシート状含水膏体を形成することができる。これにより、 本発明の貼付剤は、製品として出荷されるまでの時間(リードタイム)を従来のシート 状含水膏体を備える貼付剤に比べて短縮でき、生産性に優れたものとなっている。 [0018] In order for the patch to be usable as a product, the water-soluble polymer in the plaster must be sufficiently bridged. That is, a predetermined time was required after the plaster base was applied on the support until the water-soluble polymer was sufficiently crosslinked. Usually, this time was 13 to 18 days at room temperature for a patch provided with a conventional sheet-like hydrogel using gelatin or polyacrylic acid or the like. On the other hand, a plaster base satisfying the above conditions (a) to (d) can form a sheet-like hydrous plaster in a shorter time than before. As a result, the patch of the present invention can reduce the time (lead time) until it is shipped as a product as compared with a patch having a conventional sheet-like hydrogel, and is excellent in productivity. .
[0019] また、本発明の貼付剤において、上記膏体基剤が、水溶性高分子として、易溶性 寒天をさらに含有することが好まし 、。 In the patch of the present invention, it is preferable that the plaster base further contains easily soluble agar as a water-soluble polymer.
[0020] ここで、「易溶性寒天」とは、 70°Cの温度において、ほぼ 100%溶解する寒天を意 味する。力かる性質を有するものであれば、寒天の組成、分子量、形態、ゼリー強度 、ゾル粘度、凝固点、 pH、吸水性、離漿性等は特に限定されない。 [0020] Here, the "soluble agar" means agar that is almost 100% soluble at a temperature of 70 ° C. The composition, molecular weight, morphology, jelly strength, sol viscosity, freezing point, pH, water absorption, syneresis and the like of the agar are not particularly limited as long as they have a powerful property.
[0021] 上記の易溶性寒天を用いることにより、従来、ゼラチン、又は、ゼラチンと寒天の両 方を用いることにより達成されていた高含水性、保型性、凝集性及び粘着性のすべ てを高い水準で満足するシート状含水膏体をより確実に形成することが可能となる。 これにより、十分な水分を含有すると共に優れた粘着力を有しかつ膏体残りが十分 に低減されている貼付剤がより有効に実現可能となる。 [0021] By using the above-mentioned readily soluble agar, conventionally, gelatin or both gelatin and agar are used. By using this method, it becomes possible to more reliably form a sheet-like hydrogel body that satisfies all of the high water content, shape retention, cohesiveness and adhesiveness achieved at a high level. This makes it possible to more effectively realize a patch having sufficient water content, excellent adhesive strength, and a sufficiently reduced plaster residue.
[0022] また、易溶性寒天を用いることにより、上記の効果を得られると共に、貼付剤の配合 における自由度を更に向上させることができる。更には、貼付剤の製造をより容易な ものにすること (低コスト化、工程の簡略ィ匕等)ができる。これらの効果が得られる理由 は、以下によるものである。 [0022] In addition, the use of readily soluble agar not only provides the above effects, but also can further improve the degree of freedom in the formulation of a patch. Further, the production of the patch can be made easier (low cost, simplified process, etc.). The reasons for these effects are as follows.
[0023] 易溶性寒天を用いると、一般の寒天を溶解する際に必要であった高温 (約 90°C以 上)が必要なくなるため、製造時での損失が大きかった揮発性又は熱分解性の成分 を効率よく膏体に配合することができる。また、揮発性又は熱分解性成分を配合する ための、寒天の溶解液を冷却する装置、エネルギー、時間等が必要なぐ製造の低 コストィ匕及び製造工程の簡略ィ匕が達成できる。さらには、製造時において、揮発性又 は熱分解性成分のみならず水分の蒸発をも十分に抑制できるので、シート状含水膏 体における各成分の含有割合を所望の範囲により確実に入れることが可能となり、優 れた品質の貼付剤をより安定して得ることが可能となる。 [0023] The use of readily soluble agar eliminates the need for the high temperature (about 90 ° C or higher) that was required for dissolving general agar, so that volatile or thermally decomposable materials that had a large loss during production were used. Can be efficiently blended into the plaster. Further, it is possible to achieve low cost manufacturing and simple manufacturing process which require an apparatus for cooling the solution of agar, energy, time and the like for mixing volatile or thermally decomposable components. Furthermore, at the time of production, evaporation of not only volatile or thermally decomposable components but also water can be sufficiently suppressed, so that the content ratio of each component in the sheet-shaped hydrogel can be surely included in a desired range. This makes it possible to obtain a patch of excellent quality more stably.
[0024] また、膏体基剤が高温 (約 90°C以上)になると、膏体基剤に含まれる架橋剤 (アルミ ニゥム化合物等の多価金属塩)の反応が必要以上に促進される等の製造時におけ る不都合が生じるおそれがある。し力しながら、易溶性寒天は溶解に高温(90°C以上 )を必要としないため、上記のような問題は十分に低減することができ、潤い感などの 使用感に十分優れると共に、膏体力 の水分の滲み出しが十分に低減されており、 力 十分な粘着力を有する貼付剤をより容易かつ確実に製造することができる。 [0024] When the temperature of the paste base becomes high (about 90 ° C or higher), the reaction of a crosslinking agent (a polyvalent metal salt such as an aluminum compound) contained in the paste base is promoted more than necessary. There is a possibility that inconvenience may occur during the production of such as. However, since easily soluble agar does not require a high temperature (90 ° C or higher) for melting, the above-mentioned problems can be sufficiently reduced, and it is sufficiently excellent in sensation such as moisture and Since the oozing of moisture of physical strength is sufficiently reduced, a patch having a sufficient adhesive strength can be manufactured more easily and reliably.
[0025] また、本発明の貼付剤において、上記膏体基剤が、水溶性高分子として、易溶性 寒天とポリアクリル酸及び Z又はその塩とを含有することが好ましい。 [0025] In the patch of the present invention, the plaster base preferably contains, as a water-soluble polymer, easily soluble agar, polyacrylic acid, Z or a salt thereof.
[0026] 上記水溶性高分子として、易溶性寒天と、ポリアクリル酸及び Z又はその塩とを組 み合わせて膏体基剤に含有させることにより、潤い感などの使用感に十分優れると共 に、膏体からの水分の滲み出しが十分に低減されており、かつ十分な粘着力を有す る貼付剤をより確実かつ容易に得ることができる。 [0027] また、本発明の貼付剤が備えるシート状含水膏体の厚さについては、用途に応じて 適宜設定することができる。例えば、顔面に用いる場合、膏体の厚さは 1. 0〜1. 6m mが好ましい。 [0026] By combining the easily soluble agar with polyacrylic acid and Z or a salt thereof as the water-soluble polymer and adding it to the plaster base, it is considered that the plaster base is sufficiently excellent in usability such as moistness. In addition, it is possible to more reliably and easily obtain a patch in which oozing of moisture from the plaster is sufficiently reduced and which has a sufficient adhesive strength. [0027] Further, the thickness of the sheet-like water-containing gypsum body included in the patch of the present invention can be appropriately set according to the application. For example, when used on the face, the thickness of the plaster is preferably 1.0 to 1.6 mm.
発明の効果 The invention's effect
[0028] 本発明によれば、所望の成分を含有し所望の pHを有する配合であっても、潤 ヽ感 などの使用感に十分優れると共に、膏体からの水分の滲み出しが十分に低減されて おり、かつ十分な粘着力を有する貼付剤を提供することができる。 [0028] According to the present invention, even if the composition contains a desired component and has a desired pH, it is sufficiently excellent in usability such as hydration and the like, and oozing of water from the plaster is sufficiently reduced. Thus, a patch having sufficient adhesive strength can be provided.
図面の簡単な説明 Brief Description of Drawings
[0029] [図 1]本発明の貼付剤の好適な一実施形態を示す斜視図である。 FIG. 1 is a perspective view showing a preferred embodiment of the patch of the present invention.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0030] 以下、図面を参照して本発明の好適な実施形態について詳細に説明する。 Hereinafter, a preferred embodiment of the present invention will be described in detail with reference to the drawings.
[0031] 図 1は、本発明の貼付剤の好適な一実施形態を示す斜視図である。図 1において、 貼付剤 1は、支持体 2と、支持体 2上に積層されたシート状含水膏体 3と、シート状含 水膏体 3上に貼着された剥離シート 4とを備えるものである。 FIG. 1 is a perspective view showing a preferred embodiment of the patch of the present invention. In FIG. 1, a patch 1 comprises a support 2, a sheet-like hydrous body 3 laminated on the support 2, and a release sheet 4 adhered to the sheet-like hydrous body 3. It is.
[0032] 本実施形態の貼付剤 1が備えるシート状含水膏体 3は、以下の条件を必須とする膏 体基剤から形成されている。 [0032] The sheet-shaped hydrogel 3 included in the patch 1 of the present embodiment is formed from a plaster base that requires the following conditions.
[0033] すなわち、上記膏体基剤は、(a)ゼラチンを実質的に含まず、(b)水分を、 70質量That is, the plaster base contains (a) substantially no gelatin, and (b) contains 70 mass% of water.
%以上含有し、(c)水溶性高分子を、 3. 0質量%〜10質量%含有し、(d)キサンタ ンガム及び Z又はポリビニルピロリドンを、 0. 01質量%〜1. 4質量%含有することが 必要である。 % Or more, (c) 3.0% to 10% by weight of a water-soluble polymer, and (d) 0.01% to 1.4% by weight of xanthan gum and Z or polyvinylpyrrolidone. It is necessary to.
[0034] 上記の条件を満足する膏体基剤から形成されたシート状含水膏体 3は、所望の成 分を含有し所望の pH (特には、 pH4〜7)を有する配合であっても、潤い感などの使 用感に十分優れると共に、膏体力 の水分の滲み出しが十分に低減されており、か つ十分な粘着力を有するものとなる。 [0034] The water-containing gypsum sheet 3 formed from a plaster base satisfying the above conditions may contain a desired component and have a desired pH (particularly, pH 4 to 7). In addition to having a sufficient feeling of use such as a feeling of moisturizing, the exudation of water in the plaster strength is sufficiently reduced, and the adhesive has sufficient adhesive strength.
[0035] また、本実施形態の貼付剤 1は、シート状含水膏体 3を備えることにより、使用する 際の利便性や取り扱 、性に優れたものとなって!/、る。 Further, the patch 1 of the present embodiment is provided with the sheet-shaped hydroplasty body 3, thereby being excellent in convenience, handling, and handling when used.
[0036] 上記膏体基剤が配合する水としては、精製水や滅菌水、天然水等を用いることが できる。このような水は、水溶性高分子及びその他の成分の分散'溶解剤として働くも のである。また、水自身も使用時および使用後の使用感を著しく向上させるなどの効 果をもたらすものである。 [0036] Purified water, sterilized water, natural water, or the like can be used as the water mixed with the plaster base. Such water acts as a dispersant for the water-soluble polymer and other components. It is. Water itself also has effects such as significantly improving the feeling of use during and after use.
[0037] 本実施形態に用いる膏体基剤は、水分含量が 70質量%以上であることが必要で ある。水分含量が 70質量%未満であると、十分な潤い感を得ることができない。また 、本実施形態においては、膏体基剤の水分含量が 75〜85質量%であることが好ま しい。水分含量が 75質量%未満であると、冷却感、ひんやり感が低下する傾向にあ り、他方、 85質量%を超えると、保型性を保つことが困難となる傾向にある。 [0037] The plaster base used in the present embodiment needs to have a water content of 70% by mass or more. If the water content is less than 70% by mass, a sufficient moist feeling cannot be obtained. In the present embodiment, it is preferable that the water content of the plaster base is 75 to 85% by mass. If the water content is less than 75% by mass, the feeling of cooling and coolness tends to decrease, while if it exceeds 85% by mass, it tends to be difficult to maintain shape retention.
[0038] 水溶性高分子としては、例えば、天然高分子、セルロース系高分子、アクリル系高 分子、ビニル系高分子等が挙げられる。 [0038] Examples of the water-soluble polymer include a natural polymer, a cellulose-based polymer, an acrylic polymer, and a vinyl-based polymer.
[0039] 天然高分子としては、易溶性寒天等の寒天、ァガロース、アルギン酸ナトリウム、ァ ルギン酸アンモ-ゥム、アラビアガム、カラギーナン、グァガム、ローカストビーンガム 、ぺクチン、トラガント、デンプン、可溶性デンプン、 13ーグルカン、プルラン、キサンタ ンガム、デキストリン、カゼイン等が挙げられる。セルロース系高分子としては、ェチル セノレロース、カノレボキシメチノレセノレロース、カノレボキシメチノレセノレロースナトリウム、ヒ ドロキシメチノレセノレロース、ヒドロキシェチノレセノレロース、ヒドロキシプロピノレセノレロー ス、ヒドロキシプロピノレエチノレセノレロース、メチノレセノレロース、ニトロセノレロース、カチ オンィ匕セルロース等が挙げられる。アクリル系高分子としては、ポリアクリル酸、ポリア クリル酸塩、ポリアクリル酸ナトリウム、カルボキシビュルポリマー、ポリアクリルアミド、 ポリアクリルアミドーアタリレート共重合体、メタクリル酸重合体等が挙げられる。ビ- ル系高分子としては、ポリビュルピロリドン、ポリビュルアルコール、ポリビュルピロリド ン、ポリビュルピロリドン ビュルアルコール共重合体、ポリビュルエーテル、メトキシ エチレン無水マレイン酸共重合体、イソブチレン無水マレイン酸共重合体、 N ビ- ルァセトアミド、 N ビュルァセトアミドとアクリル酸及び Z又はアクリル酸塩との共重 合体等が挙げられる。また、その他として、カルボキシメチルアミロース、ポリエチレン オキサイド等が挙げられる。これらは、一種を単独で又は二種以上を組合せて用いる ことができる。 [0039] Examples of natural polymers include agar such as readily soluble agar, agarose, sodium alginate, ammonium alginate, gum arabic, carrageenan, guar gum, locust bean gum, pectin, tragacanth, starch, soluble starch, 13-glucan, pullulan, xanthan gum, dextrin, casein and the like. Examples of cellulosic polymers include etyl cenorellose, canoleboxy methinoresenolerose, canolevoxy methinoresenolerose sodium, hydroxymethinoresenolerose, hydroxyethinoresenorelose, hydroxypropinoresenorelose, and hydroxy. Propinoleetinoresenolerose, methinoresenolerose, nitrosenorelose, kathioni dani cellulose and the like. Examples of the acrylic polymer include polyacrylic acid, polyacrylate, sodium polyacrylate, carboxybutyl polymer, polyacrylamide, polyacrylamide-acrylate copolymer, and methacrylic acid polymer. Examples of the vinyl polymer include polyvinylpyrrolidone, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpyrrolidone vinyl alcohol copolymer, polyvinyl ether, methoxyethylene maleic anhydride copolymer, and isobutylene maleic anhydride copolymer. Examples thereof include polymers, N-vinylacetamide, and copolymers of N-butylacetamide with acrylic acid and Z or acrylate. Other examples include carboxymethyl amylose and polyethylene oxide. These can be used alone or in combination of two or more.
[0040] 本実施形態に用いる膏体基剤にぉ 、ては、キサンタンガム及び Z又はポリビニル ピロリドンが合計で 0. 01質量%〜1. 4質量%の範囲内で膏体基剤に配合されてお り、かつ配合する水溶性高分子の合計が膏体基剤中で 3. 0質量%〜10質量%であ れば、キサンタンガム及びポリビュルピロリドン以外に用いる水溶性高分子の種類及 びその配合量にっ 、ては特に限定されな 、。 [0040] In the plaster base used in the present embodiment, xanthan gum and Z or polyvinylpyrrolidone are mixed with the plaster base in a total amount of 0.01% by mass to 1.4% by mass. You If the total amount of the water-soluble polymer to be blended is 3.0% by mass to 10% by mass in the paste base, the type and amount of the water-soluble polymer used in addition to xanthan gum and polybutylpyrrolidone It is not particularly limited.
[0041] 本実施形態においては、水溶性高分子が、易溶性寒天とポリアクリル酸及び Z又 はその塩を含有することが好まし!/、。 In the present embodiment, the water-soluble polymer preferably contains easily soluble agar and polyacrylic acid and Z or a salt thereof!
[0042] さらに、本実施形態に用いる易溶性寒天は、ゼリー強度が 390〜1200gZcm2の 寒天が好ましぐ 500〜800gZcm2力より好ましく、 650〜750g/cm2が特に好まし い。易溶性寒天のゼリー強度が 390gZcm2未満であると、保型性が低下する傾向に ある。一方、ゼリー強度が 1200gZcm2を超えると、膏体が硬くて脆い物性になる傾 I口」にある。 [0042] In addition, readily soluble agar used in the present embodiment, the jelly strength is more preferably agar preferred instrument 500~800GZcm 2 force 390~1200gZcm 2, 650~750g / cm 2 is not particularly preferred. If the jelly strength of the easily soluble agar is less than 390 gZcm 2 , the shape retention tends to decrease. On the other hand, when the jelly strength exceeds 1200 gZcm 2 , the plaster becomes hard and brittle.
[0043] また、上記易溶性寒天は、ァガロぺクチンをほとんど含有しな 、寒天が好ま 、。ァ ガロぺクチンはイオン性官能基を多く含んでおり、ゲル化能をほとんど有して 、な 、。 そのため、ァガロぺクチンをほとんど含有しない易溶性寒天は、より少ない配合量で 効率よくゲルィ匕を行うことができ、溶解させることもより容易となることカゝら好ましい。 [0043] The easily soluble agar preferably contains almost no agaropectin, and is preferably agar. Agaropectin contains a large amount of ionic functional groups and has almost gelling ability. For this reason, the easily soluble agar containing almost no agaropectin is preferable because it can efficiently perform gelling with a smaller amount of compounding and can be more easily dissolved.
[0044] 本実施形態で用いられる易溶性寒天としては、公知のものを用いることができ、商 業的に入手可能なものとしては、例えば、「UP— 37K」、伊那食品工業株式会社製 、ゼリー強度: 700g/cm2)、「UP— 26K」、伊那食品工業株式会社製、ゼリー強度 : 650g/cm2)、「UP— 16K」、伊那食品工業株式会社製、ゼリー強度: 600g/cm 2)、「UZ— 5K」、伊那食品工業株式会社製、ゼリー強度 :420g/cm2)、「UM— 11 K」、伊那食品工業株式会社製、ゼリー強度:1000g/cm2)等が挙げられる。 As the readily soluble agar used in the present embodiment, known ones can be used, and commercially available ones include, for example, “UP-37K”, manufactured by Ina Food Industry Co., Ltd. jelly strength: 700g / cm 2), "UP- 26K", Ina Food Industry Co., Ltd., jelly strength: 650g / cm 2), "UP- 16K", Ina Food Industry Co., Ltd., jelly strength: 600g / cm 2), “UZ-5K”, manufactured by Ina Food Industry Co., Ltd., jelly strength: 420 g / cm 2 ), “UM-11 K”, manufactured by Ina Food Industry Co., Ltd., jelly strength: 1000 g / cm 2 ) Can be
[0045] 上記易溶性寒天とポリアクリル酸及び Z又はその塩の配合量については、膏体基 剤において、易溶性寒天とポリアクリル酸及び Z又はその塩の合計が 3〜8質量%で あることが好ましい。上記合計が 3質量%未満であると、膏体が軟らカ、くなる傾向にあ り、 8質量%を超えると、膏体が硬くなる傾向にある。 [0045] With respect to the compounding amount of the above-mentioned easily soluble agar and polyacrylic acid and Z or a salt thereof, the total of the easily soluble agar and polyacrylic acid and Z or a salt thereof is 3 to 8% by mass in the paste base. Is preferred. If the above total is less than 3% by mass, the plaster tends to be soft, and if it exceeds 8% by mass, the plaster tends to be hard.
[0046] 更に、易溶性寒天と、ポリアクリル酸及び Z又はその塩の合計とが、質量比で 1: 8 〜1 : 16であることが好ましい。易溶性寒天の割合が、 1Z16未満であると、保型性が 低下する傾向にあり、 1Z8を超えると、膏体が硬くて脆い物性になる傾向にある。 [0046] Further, it is preferable that the mass of the easily soluble agar and the sum of polyacrylic acid and Z or a salt thereof is 1: 8 to 1:16. If the proportion of readily soluble agar is less than 1Z16, the shape retention tends to decrease, and if it exceeds 1Z8, the plaster tends to be hard and brittle.
[0047] 本実施形態で用いる膏体基剤には、水分及び上記水溶性高分子以外に、必要に 応じて、薬効成分、化粧成分、及び膏体に一般的に配合され得る諸成分を含有させ てもよい。膏体に一般的に配合され得る諸成分としては、多価アルコール、多価金属 塩、界面活性剤等が挙げられる。 [0047] The plaster base used in the present embodiment includes, in addition to water and the water-soluble polymer, Accordingly, a medicinal component, a cosmetic component, and various components that can be generally blended into a plaster may be contained. Examples of the components that can be generally blended into the plaster include polyhydric alcohols, polyvalent metal salts, and surfactants.
薬効成分としては、インドメタシン、ケトプロフェン、フルルビプロフェン、フェルナビ ク、ケトロラタ、ジクロフェナクナトリウム等の消炎鎮痛剤;塩酸ダラ-セトロン、塩酸ァ ザセトロン、塩酸オンダンセトロン、塩酸ラモセトロン等の制吐剤;エストラジオール、 エストロン、エストリオール、ェキリン、ェキレニン、及びこれらの誘導体、プロゲステロ ン、力プロン酸ヒドロキシプロゲステロン、酢酸ヒドロキシプロゲステロン、ジドロゲステ ロン、酢酸クロルマジノン、ェチステロン、ジメチステロン、ノルェチステロン、酢酸ノル ェチステロン、ェナント酸ノルェチステロン、酢酸ェチノジオール、酢酸メゲストロール 及びァリルエストレノール等のホルモン剤;塩酸ォキシプチニン等の頻尿治療剤;二 フエジピン、二ゾルジピン、二カルジピン、 -トレジピン等の Ca拮抗剤;ヒドロコルチゾ ン、プレドニゾロン、プロピオン酸クロベタゾール等のコルチコステロイド類;フエノバル ピタール、トリァゾラム、ニトラゼパム、ロラゼパム等の催眠鎮静剤;フルフエナジン、ジ ァゼパム、クロルプロマジン等の精神安定剤;クロ-ジン、塩酸クロ-ジン、ピンドロー ル、プロプラノロール、二トレンジピン、メトプロロール等の抗高血圧剤;ノヽイド口サイァ ザイド等の降圧利尿剤;ペニシリン、テトラサイクリン、エリスロマイシン、クロラムフエ- コール等の抗生物質;リドカイン、塩酸ジブ力イン、ァミノ安息香酸ェチル等の麻酔剤 ;塩酸ベンザルコ-ゥム、クロトリマゾール等の抗菌性物質、ビタミン A等のビタミン剤; ニトラゼパム等の抗てんかん剤;ニトログリセリン、硝酸イソソルビド等の冠血管拡張剤 ;ジフェンヒドラミン、クロルフエ-ラミン等の抗ヒスタミン剤;塩酸ッロブテロール、サル ブタモール、フマル酸ケトチフェン、トラ-ラスト、塩酸イソプロテレノロール等の鎮咳 剤;塩酸クロミプラン、塩酸アミトリプチリン等の抗鬱剤;メシル酸ジヒドロェルゴトキシ ン、ィフェンプロジル等の脳循環改善剤; 5 -フルォロウラシル等の抗腫瘍剤;ェペリ ゾン、ダントロレン等の筋弛緩剤;フェンタニール、モルヒネ等の鎮痛剤;ルーティイナ イジングホルモン リリージングホルモン(LH—RH)、サイロトロピンリリージングホル モン (TRH)等のポリペプチド系のホルモン剤;抹消血管拡張剤;ポリサッカライド類、 オーラノフィン、口ベンザリット等の免疫調節剤;ウルゾデスォキシコール酸等の利胆 剤;ヒドロフルメチアジド等の利尿剤;トリブタミド等の糖尿病用剤;コルヒチン等の通風 治療剤;ァマンタジン、レボドパ等の抗パーキンソン剤;ジフエ-ドール、ベタヒスチン 等の抗めまい剤、等の薬物が挙げられる。これらの薬物は、相互作用による不都合 が生じない場合、必要に応じて 2種以上を組み合わせて用いることができる。 Pharmaceutical ingredients include anti-inflammatory analgesics such as indomethacin, ketoprofen, flurbiprofen, fernavik, ketorolata, diclofenac sodium; anti-emetic agents such as dara-setron hydrochloride, azasetron hydrochloride, ondansetron hydrochloride, ramosetron hydrochloride; estradiol, Estrone, estriol, equilin, echirenine, and their derivatives, progesterone, hydroxyprogesterone dyprosate, hydroxyprogesterone acetate, dydrogesterone acetate, chlormadinone acetate, ethisterone, dimethylesterone, norethisterone, norethisterone acetate, norletosterone enanthate, ethendiol acetate Hormonal agents such as megestrol acetate and allylestrenol; therapeutic agents for pollakiuria such as oxiptinin hydrochloride; Ca antagonists such as pin, dicardipine and -tredipine; corticosteroids such as hydrocortisone, prednisolone and clobetasol propionate; hypnotics and sedatives such as phenovalpital, triazolam, nitrazepam, lorazepam; flufenadine, diazepam, chlorpromazine and the like Tranquilizer; antihypertensives such as clodin, clodin hydrochloride, pindolol, propranolol, ditolendipine, metoprolol; antihypertensive diuretics such as noid mouth thiazide; penicillin, tetracycline, erythromycin, chloramphenol Antibiotics; Lidocaine, dibuforce hydrochloride, anesthetics such as aminoethyl benzoate; antibacterial substances such as benzalco-dum hydrochloride and clotrimazole; vitamins such as vitamin A; antiepileptic drugs such as nitrazepam; Coronary vasodilators such as lyserin and isosorbide dinitrate; antihistamines such as diphenhydramine and chlorphen-lamin; antitussives such as rlobbuterol hydrochloride, salbutamol, ketotifen fumarate, tra-last and isoproterenol hydrochloride; clomiplan hydrochloride and amitriptyline hydrochloride Cerebral circulation improving agents such as dihydroerggotoxine mesylate and ifenprodil; antitumor agents such as 5-fluorouracil; muscle relaxants such as eperisone and dantrolene; analgesics such as fentanyl and morphine; Polypeptide hormones such as releasing hormone (LH-RH) and thyrotropin releasing hormone (TRH); peripheral vasodilators; immunomodulators such as polysaccharides, auranofin, and oral benzarit; urzo Desoxycholic acid, etc. Bold Drugs such as diuretics such as hydroflumethiazide; diabetic agents such as tributamide; ventilation agents such as colchicine; antiparkinson agents such as amantadine and levodopa; and anti-vertigo agents such as diphen-dol and betahistine. . These drugs can be used in combination of two or more as necessary if no inconvenience due to the interaction occurs.
[0049] 上記の薬効成分の配合量につ!、ては、用いる薬物や用途によっても異なるが、膏 体基剤中に 0. 01〜10質量%配合されることが好ましい。また、例えば、薬効成分と してプラセンタエキスを用いる場合、膏体基剤中で、 0. 05〜0. 5質量%であることが 好ましぐ 0. 1〜0. 4質量%であることがより好ましい。プラセンタエキスの配合割合 力 0. 05質量%未満であると、効能が得られにくい傾向にあり、他方、 0. 5質量%を 超えると、求められる効能に対して過剰な量となる傾向にある。 [0049] The amount of the above-mentioned medicinal component is preferably 0.01 to 10% by mass in the plaster base, although it depends on the drug used and the use. In addition, for example, when a placenta extract is used as a medicinal ingredient, the amount is preferably 0.05 to 0.5% by mass in the plaster base, and 0.1 to 0.4% by mass is preferred. Is more preferred. If the amount of placenta extract is less than 0.05% by mass, the effect tends to be difficult to obtain, while if it exceeds 0.5% by mass, the amount tends to be excessive for the required effect. .
[0050] 化粧成分としては、アラントイン、ァスコルビン酸、ァスコルビン酸誘導体、マロニエ エキス、水溶性プラセンタエキス、セージエキス、コウジ酸、レシチン、アミノ酸類、ホ ルモン類、胎盤抽出物、ビタミン A、ビタミン D、ビタミン E及びこれらの誘導体、グリチ ルリチン酸ジカリウム、カフェイン酸、及び、果汁エキス等が挙げられる。 [0050] Cosmetic components include allantoin, ascorbic acid, ascorbic acid derivatives, malonie extract, water-soluble placenta extract, sage extract, kojic acid, lecithin, amino acids, hormones, placenta extract, vitamin A, vitamin D, Examples include vitamin E and their derivatives, dipotassium glycyrrhizinate, caffeic acid, and fruit juice extracts.
[0051] また、本実施形態に用いる膏体基剤が上記易溶性寒天を配合する場合には、寒天 を溶解するための高温 (約 90°C以上)が必要ないため、製造時での損失が大きかつ た揮発性又は熱分解性の成分を好適に配合することができる。 When the paste base used in the present embodiment incorporates the above-mentioned readily soluble agar, a high temperature (about 90 ° C. or higher) for dissolving the agar is not required, so that the loss during production is A volatile or thermally decomposable component having a large particle size can be suitably blended.
[0052] 揮発性成分としては、熱 (例えば、約 90°C以上の熱)を付与することにより揮発する 成分であればよぐ例えば、ユーカリ油、二クズク油、チアミン油、ハツ力油、メントール 、カンフル、ピネン、ボルネオール、リモネン等のテルペン類、ラベンダー、ペパーミン ト、ハツ力、ゼラ-ゥム、ライム、カモミール等のハーブ精油、エチルアルコール、イソ プロピルアルコール等の低級アルコール、フレグランス、フレーバー等の着香料、亜 硝酸ァミル、トリメタジオン等の薬物及びィ匕粧料、イソステアリン酸、オクタン酸、及び ォレイン酸等の C8〜C22の脂肪酸、ォレイルアルコール及びラウリルアルコール等 の C8〜C22の脂肪酸アルコール、ォレイン酸ェチル、ミリスチン酸イソプロピル、ステ アリン酸ブチル、及びラウリン酸メチル等の C8〜C22の脂肪酸の低級アルキルエス テル、アジピン酸ジイソプロピル等の C6〜C8二酸のジアルキルエステル、グリセリル モノラウレート等の C8〜C22の脂肪酸モノグリセリド、テトラヒドロフルフリルアルコー ノレポリエチレングリコーノレエーテル、ポリェナリングリコール、プロピレングリコール、 2 一(2—エトキシエトキシ)エタノール、ジエチレングリコールモノメチルエーテル、及び これらの混合物からなる液体の賦形剤等が挙げられる。 [0052] As the volatile component, any component that can be volatilized by applying heat (for example, heat of about 90 ° C or more) may be used. For example, eucalyptus oil, dirt oil, thiamine oil, heart oil, Terpenes such as menthol, camphor, pinene, borneol, limonene, lavender, peppermint, hatatsu, herbal essential oils such as zeradium, lime, chamomile, lower alcohols such as ethyl alcohol and isopropyl alcohol, fragrances and flavors Flavoring agents, drugs such as amyl nitrite and trimetadione and cosmetics, C8-C22 fatty acids such as isostearic acid, octanoic acid, and oleic acid; C8-C22 fatty alcohols such as oleyl alcohol and lauryl alcohol; Ethyl oleate, isopropyl myristate, butyl stearate, and methyl laurate Lower alkyl S. ethers of fatty acids C8-C22, dialkyl esters of C6~C8 diacid diisopropyl adipate, fatty acid monoglycerides C8-C22, such as glyceryl monolaurate, tetrahydrofurfuryl alcohol Liquid polyethylene excipients such as polyethylene glycol glycol ether, polyethylene glycol, propylene glycol, 21- (2-ethoxyethoxy) ethanol, diethylene glycol monomethyl ether, and mixtures thereof.
[0053] これらの配合量は、例えば、メントールを用いる場合、膏体基剤中で、 0. 005-5. [0053] For example, when menthol is used, the amount of these components is 0.005-5.
0質量%であることが好ましぐ 0. 01〜2. 0質量%であることがより好ましい。メントー ルの配合割合が、 0. 005質量%未満であると、メントールの薬効が得られに《なる 傾向にあり、他方、 5. 0質量%を超えると、膏体からの染み出しが生じやすくなる傾 I口」にある。 It is more preferably 0% by mass, more preferably 0.01% to 2.0% by mass. If the blending ratio of menthol is less than 0.005% by mass, the medicinal effect of menthol tends to be obtained, while if it exceeds 5.0% by mass, menthol is likely to exude from the plaster. It's in the way.
[0054] 熱分解性成分としては、熱 (例えば、約 90°C以上の熱)に不安定な物質であればよ く、例えば、ジクロフエナク、フエルビナク、インドメタシン、ケトプロフェン等のカルボン 酸基を持つ非ステロイド系消炎鎮痛剤、プロスタグラジン類、アルブミン等のたんぱく 質、ジフテリア毒素等の毒素、カタラーゼ等の酵素、シクロスポリン八、ヒルジン、ソマト スタチン、チモペンチン等のペプチド、エストロゲン等のホルモン、ヒト成長ホルモン、 ブタ成長ホルモン、ゥシ成長ホルモン、ヒトカルシトニン、サケカルシトニン、カルボ力 ルシトニン、及びインスリン等のペプチドホルモン、ホルモンのアンタゴニスト、ァセチ ルコリン等の神経伝達物質、神経伝達物質のアンタゴ-スト、ヒアルロン酸等の糖タ ンパク質、 (Xーリポタンパク等のリポタンパク質、 IgG等の免疫グロブリン、インターフ ヱロン及びインターロイキン等の免疫調節薬、エストロゲン受容体タンパク質等の細 胞の受容体、非分画へパリン、低分子へパリン、コンドロイチン 4 硫酸、コンドロイ チン 6—硫酸、及びこれらの誘導体等のグリコサミノダリカン類、プロスタグランジン 、朝鮮人参、アル-力、キンセン力等の植物エキス、セレニウム酵母、ビール酵母等 の酵母、オボアルブミン、ゼラチン等の動物性タンパク質、ダルテン等の植物性タン パク質、加水分解コラーゲン、加水分解小麦ダルテン等の動物又は植物性タンパク 質の加水分解物、ヒアルロン酸等の天然多糖類、レシチン、コラーゲン、プラセンタエ キス、ァスコルビン酸及びそのエステル、レチノール及びそのエステル、ビタミン A油 、酢酸ヒドロキソコバラミン、ェルゴカルシフエノール等のビタミン類、硝酸イソソルビド 、ニトログリセリン、ェナント酸テストステロン、酒石酸エルゴタミン、ペルゴリド、 -コチ ン、亜硝酸アルミ、ェチクロルビノール、パラメタジオン、スコポラミン等が挙げられる。 [0055] これらの配合量は、例えば、ケトプロフェンを用いる場合、膏体基剤中で、 0. 01〜 5. 0質量%であることが好ましぐ 0. 1〜1. 0質量%であることがより好ましい。ケトプ 口フェンの配合割合力 0. 01質量%未満であると、ケトプロフェンの薬効が得られに くくなる傾向にあり、他方、 5. 0質量%を超えると、求める薬効に対して過剰な配合量 となる傾向にある。 [0054] The thermally decomposable component may be any substance that is unstable to heat (eg, heat of about 90 ° C or higher). For example, non-functional compounds having a carboxylic acid group such as diclofenac, fuerbinac, indomethacin, and ketoprofen may be used. Steroidal anti-inflammatory drugs, prostaglandins, proteins such as albumin, toxins such as diphtheria toxin, enzymes such as catalase, cyclosporine 8, hirudin, somatostatin, peptides such as thymopentin, hormones such as estrogen, human growth hormone, Peptide hormones such as porcine growth hormone, pest growth hormone, human calcitonin, salmon calcitonin, carboxylucitonin and insulin, hormone antagonists, neurotransmitters such as acetylcholine, neurotransmitters antagonists, hyaluronic acid, etc. Glycoprotein, (X-lipoprotein Lipoproteins, immunoglobulins such as IgG, immunomodulators such as interferon and interleukin, cellular receptors such as estrogen receptor protein, unfractionated heparin, low-molecular-weight heparin, chondroitin 4-sulfate, chondroitin Tin 6-sulfuric acid, glycosaminodalicans such as derivatives thereof, plant extracts such as prostaglandins, ginseng, al-force, kinsen-force, yeasts such as selenium yeast, brewer's yeast, ovalbumin, gelatin, etc. Animal proteins, vegetable proteins such as dalten, hydrolyzed collagen, hydrolysates of animal or vegetable proteins such as hydrolyzed wheat dartene, natural polysaccharides such as hyaluronic acid, lecithin, collagen, placenta kiss, Ascorbic acid and its esters, retinol and its esters, vitamin A Oils, vitamins such as hydroxocobalamin acetate, ergocalcifenol, isosorbide dinitrate, nitroglycerin, testosterone enanthate, ergotamine tartrate, pergolide, -cotin, aluminum nitrite, ethichlorbinol, paramethadione, scopolamine, etc. Can be [0055] For example, when ketoprofen is used, the compounding amount is preferably 0.01 to 5.0% by mass in the plaster base, and is 0.1 to 1.0% by mass. Is more preferable. If the mixing ratio of ketoprofen is less than 0.01% by mass, the medicinal effect of ketoprofen tends to be difficult to obtain, while if it exceeds 5.0% by mass, the compounding amount is excessive with respect to the desired medicinal effect. It tends to be.
[0056] 多価アルコールとしては、例えば、グリセリン、ポリエチレングリコール、 1, 3—ブチ レングリコール、プロピレングリコール、ジプロピレングリコール、ソルビトール、及びキ シリトール等が挙げられる。この中でも特に、グリセリンが作業性や使用感等が良好で ある点で好ましい。 [0056] Examples of the polyhydric alcohol include glycerin, polyethylene glycol, 1,3-butylene glycol, propylene glycol, dipropylene glycol, sorbitol, and xylitol. Among them, glycerin is particularly preferred in that it has good workability and usability.
[0057] 多価アルコールの配合量は、膏体基剤中で、 5〜15質量%であることが好ましぐ 8 〜12質量%であることがより好ましい。配合割合が 5質量%未満であると、膏体が硬 くなる傾向にあり、他方、 12質量%を超えると、膏体からの水分の滲み出しが生じや すくなる傾向にある。 [0057] The blending amount of the polyhydric alcohol in the paste base is preferably 5 to 15% by mass, more preferably 8 to 12% by mass. If the blending ratio is less than 5% by mass, the plaster tends to be hard, while if it exceeds 12% by mass, the oozing of water from the plaster tends to occur.
[0058] 多価金属塩としては、例えば、水酸ィ匕アルミニウム、水酸ィ匕アルミニウムゲル、含水 ケィ酸アルミニウム、合成ケィ酸アルミニウム、カオリン、酢酸アルミニウム、乳酸アルミ ユウム、ステアリン酸アルミニウム、塩化カルシウム、塩化マグネシウム、塩化アルミ- ゥム、ジヒドロキシアルミニウムァミノアセテート、メタケイ酸アルミン酸マグネシウム、及 びケィ酸アルミン酸マグネシウム等が挙げられる。これらは、 1種を単独で又は 2種以 上を組み合わせて用いることができる。この中でも特に、ジヒドロキシアルミニウムアミ ノアセテート、合成ケィ酸アルミニウム及びメタケイ酸アルミン酸マグネシウムが好まし い。 Examples of the polyvalent metal salt include aluminum hydroxide, aluminum hydroxide gel, hydrated aluminum silicate, synthetic aluminum silicate, kaolin, aluminum acetate, aluminum lactate, aluminum stearate, and calcium chloride. , Magnesium chloride, aluminum chloride, dihydroxyaluminum amino acetate, magnesium metasilicate aluminate, magnesium silicate aluminate and the like. These can be used alone or in combination of two or more. Of these, dihydroxyaluminum aminoacetate, synthetic aluminum silicate and magnesium metasilicate aluminate are particularly preferred.
[0059] 多価金属塩の配合量は、膏体基剤中で、 0. 01〜1質量%であることが好ましぐ 0 . 02〜0. 5質量%であることがより好ましい。配合割合が 0. 01質量%未満であると、 反応が十分に進行せずゲル強度が不十分となる傾向にあり、他方、 1質量%を超え ると、製造時における反応速度が早過ぎてゲルイ匕が不均一となり作業性が低下したり 、膏体の粘着性が不十分となる傾向にある。 [0059] The compounding amount of the polyvalent metal salt is preferably 0.01 to 1% by mass, more preferably 0.02 to 0.5% by mass, in the paste base. If the compounding ratio is less than 0.01% by mass, the reaction does not proceed sufficiently and the gel strength tends to be insufficient. On the other hand, if it exceeds 1% by mass, the reaction rate during production is too fast. There is a tendency for the gelling to be uneven and the workability to be reduced, or the adhesiveness of the plaster to be insufficient.
[0060] 界面活性剤としては、例えば、ジォクチルスルホコハク酸ナトリウム、アルキルサル フエ—ト塩、 2—ェチルへキシルアルキル硫酸エステルナトリウム塩、ノルマルドデシ ルベンゼンスルホン酸ナトリウム等の陰イオン界面活性剤;へキサデシルトリメチルァ ンモ -ゥムクロライド、ォクタデシルジメチルベンジルアンモ -ゥムクロライド、ポリオキ シエチレンドデシルモノメチルアンモ -ゥムクロライド等の陽イオン界面活性剤;ポリオ キシエチレンステアリルエーテル、ポリオキシエチレン硬化ヒマシ油、ポリオキシェチ レントリデシルエーテル、ポリオキシエチレンノニルフエニルエーテル、ポリオキシェチ レンォクチルフエ-ルエーテル、モノステアリン酸ポリエチレングリコールなどのポリオ キシエチレンモノステアレート、ソルビタンモノステアレート、ソルビタンモノパルミネー ト、ソルビタンセスキォレエート、ポリオキシエチレンソルビタンモノラウレート、ポリオキ シエチレンソルビタンモノォレエート、グリセロールモノステアレート、ポリグリセリン脂 肪酸エステル、ポリオキシエチレンォクタデシルァミン等の非イオン界面活性剤等が 挙げられる。これらは、 1種を単独で又は 2種以上を組み合わせて用いることができる 。この中でも特に、モノステアリン酸ポリエチレングリコール、ポリオキシエチレン硬化 ヒマシ油、及びモノォレイン酸ポリオキシエチレンソルビタンが好まし 、。 [0060] Examples of the surfactant include sodium octyl sulfosuccinate, alkyl sulfate salt, 2-ethylhexyl alkyl sulfate sodium salt, and normal dodecyl ester. Anionic surfactants such as sodium benzenesulfonate; cationic surfactants such as hexadecyltrimethylammonium-dimethyl chloride, octadecyldimethylbenzylammonium-dimethyl chloride, polyoxyethylene dodecyl monomethylammonium-dimethyl chloride; polyoxyethylene Polyoxyethylene monostearate, sorbitan monostearate, sorbitan monostearate, such as stearyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene tridecyl ether, polyoxyethylene nonyl phenyl ether, polyoxyethylene octyl phenyl ether, and polyethylene glycol monostearate Palmitate, sorbitan sesquioleate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan Examples include nonionic surfactants such as nooleate, glycerol monostearate, polyglycerin fatty acid ester, and polyoxyethylene octadecylamine. These can be used alone or in combination of two or more. Among these, polyethylene glycol monostearate, polyoxyethylene hydrogenated castor oil, and polyoxyethylene sorbitan monooleate are particularly preferred.
[0061] 界面活性剤の配合量は、膏体基剤中で、 0. 01〜5質量%であることが好ましぐ 0 . 1〜2質量%であることがより好ましい。配合割合が 0. 01質量%未満であると、プリ ードを起こしやすくなる傾向にあり、他方、 5質量%を超えると、保型性を保つことが 困難となる傾向がある。 [0061] The blending amount of the surfactant is preferably from 0.01 to 5% by mass, more preferably from 0.1 to 2% by mass in the plaster base. If the blending ratio is less than 0.01% by mass, pread tends to occur, while if it exceeds 5% by mass, it tends to be difficult to maintain the shape retention.
[0062] 更に、本実施形態で用いる膏体基剤には、必要に応じて、美肌成分、保湿成分、 酸化防止剤、架橋剤、防腐剤、粘着付与剤、溶解剤、色素、香料、紫外線吸収剤、 無機充填剤及び pH調整剤等を配合することも可能である。 [0062] Further, the plaster base used in the present embodiment may include, if necessary, a skin-skinning component, a moisturizing component, an antioxidant, a cross-linking agent, a preservative, a tackifier, a dissolving agent, a pigment, a fragrance, an ultraviolet ray. It is also possible to incorporate an absorbent, an inorganic filler, a pH adjuster, and the like.
[0063] 美肌成分としては、例えば、アロエエキス、エイジッエキス、オレンジエキス、キイチ ゴエキス、キウイエキス、キューカンバーエキス、クチナシエキス、力ミツレエキス、サン ザシエキス、セィヨウネズエキス、タイソゥエキス、デュークエキス、トマトエキス、へチ マエキス、サクシネルケフイラン、マレイルケフイラン、麦芽根エキス、バラエキス、コラ 一ゲン、セラミド、スクヮラン、ヒアルロン酸、アラントイン、マロニエエキス、水溶性プラ センタエキス、ビタミン A、ビタミン B類、ビタミン C、ビタミン D及びビタミン E等のビタミ ン類、コウジ酸等が挙げられる。これらは、 1種を単独で又は 2種以上を組み合わせ て用いることができる。 [0064] また、上記以外には、ボタンピ、カツコン、シャタヤク、トウキ、センキユウ、チヨウジ、 センブリ、ソウジユウ、チンピ、ビヤクジュッ、トウヒ、ケィヒ、ォゥレン、ォォバタ、イチヨウ 等の生薬成分、ベントナイト、モンモリロナイト、サボナイト、ヘクトライト等の泥成分な どが挙げられる。 [0063] Examples of the beautiful skin component include aloe extract, age extract, orange extract, raspberry extract, kiwi extract, cucumber extract, gardenia extract, potato beetle extract, hawthorn extract, sycamore extract, taiso extract, duke extract, and tomato extract. Chima extract, saciner kefuirane, maleile kefuirane, malt root extract, rose extract, collagen, ceramide, squalane, hyaluronic acid, allantoin, malonier extract, water-soluble placenta extract, vitamin A, vitamin B, vitamin C , Vitamin D such as vitamin D and vitamin E, and kojic acid. These can be used alone or in combination of two or more. [0064] In addition to the above, crude drug components such as red bean, katsukon, shatayaku, touki, senkiyu, chiyouji, assembly, soujiyuu, chimpi, biyakuju, spruce, keihi, orelen, obatta, ichiyou, etc., bentonite, montmorillonite, sabonite, Examples include mud components such as hectorite.
[0065] 保湿成分としては、例えば、ァシル化ケフイラン水溶液、麦芽エキス、尿素、グリコー ル類が挙げられる。これらは、 1種を単独で又は 2種以上を組み合わせて用いること ができる。 [0065] Examples of the moisturizing component include an aqueous solution of acylated kefuirane, malt extract, urea, and glycols. These can be used alone or in combination of two or more.
[0066] 酸化防止剤としては、例えば、ァスコルビン酸、没食子酸プロピル、ブチルヒドロキ シァ-ノール、ジブチルヒドロキシトルエン、ノルジヒドログアヤレチン酸、トコフェロー ル、酢酸トコフエロール、天然ビタミン E、亜硝酸ナトリウム、及び亜硝酸水素ナトリウム 等が挙げられる。 [0066] Antioxidants include, for example, ascorbic acid, propyl gallate, butylhydroxylanol, dibutylhydroxytoluene, nordihydroguaiaretinic acid, tocopherol, tocopherol acetate, natural vitamin E, sodium nitrite, And sodium hydrogen nitrite.
[0067] 架橋剤としては、例えば、水難溶性アルミニウム化合物、多官能性エポキシ化合物 、アミノ榭脂、フエノール榭脂、エポキシ榭脂、アルキド榭脂、不飽和ポリエステル等 の熱硬化性榭脂、イソシァネートイ匕合物、ブロックイソシァネートイ匕合物、有機系架橋 剤、金属又は金属化合物等の無機系架橋剤が挙げられる。これらは、 1種を単独で 又は 2種以上を組み合わせて用いることができる。 Examples of the crosslinking agent include thermosetting resins such as hardly water-soluble aluminum compounds, polyfunctional epoxy compounds, amino resins, phenol resins, epoxy resins, alkyd resins, and unsaturated polyesters, and isocyanate resins. Compounds, block isocyanate conjugates, organic crosslinking agents, and inorganic crosslinking agents such as metals or metal compounds. These can be used alone or in combination of two or more.
[0068] 防腐剤としては、例えば、ノラオキシ安息香酸ェチル、パラォキシ安息香酸プロピ ル、パラォキシ安息香酸ブチル、ソルビン酸、及びデヒドロ酢酸等が挙げられる。 [0068] Examples of the preservatives include ethyl ethyl noraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, sorbic acid, dehydroacetic acid, and the like.
[0069] 粘着付与剤としては、例えば、カゼイン、プルラン、デキストラン、アルギン酸ソーダ 、可溶性デンプン、カルボキシデンプン、デキストリン、カルボキシメチルセルロース、 カノレボキシメチノレセノレロースナトリウム、メチノレセノレロース、ェチノレセノレロース、ヒドロ キシェチルセルロース、ポリビニールアルコール、ポリエチレンオキサイド、ポリアタリ ルアミド、ポリアクリル酸、ポリビニルピロリドン、カルボキシビ二ルポリマー、ポリビニル エーテル、ポリマレイン酸共重合体、メトキシエチレン無水マレイン酸共重合体、イソ ブチレン無水マレイン酸共重合体、ポリエチレンィミン、ポリビニールアルコール部分 ケンィ匕物、ヒドロキシプロピルメチルセルロース、キサンタンガム、 N—ビュルァセトァ ミド等が挙げられる。 [0069] Examples of the tackifier include casein, pullulan, dextran, sodium alginate, soluble starch, carboxystarch, dextrin, carboxymethylcellulose, canoleboxy methinoresenorelose sodium, methinoresenorelose, etinoresenorelose. , Hydroxyethyl cellulose, polyvinyl alcohol, polyethylene oxide, polyatarylamide, polyacrylic acid, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, polymaleic acid copolymer, methoxyethylene maleic anhydride copolymer, isobutylene anhydride Maleic acid copolymer, polyethyleneimine, polyvinyl alcohol part Kenyidani, hydroxypropyl methylcellulose, xanthan gum, N-butyl acetate Etc. The.
[0070] 溶解剤としては、例えば、セバシン酸ジェチル、 N—メチルー 2—ピロリドン、サリチ ル酸メチル、サリチル酸グリコール、トリァセチン、ォレイルアルコール、ベンジルアル コール、ミリスチン酸イソプロピル、アジピン酸ジイソプロピル、クロタミトン、ハツ力油、 ツバキ油、ヒマシ油、及びォリーブ油等が挙げられる。 [0070] Examples of the solubilizer include getyl sebacate, N-methyl-2-pyrrolidone, and salici. Examples include methyl luate, glycol salicylate, triacetin, oleyl alcohol, benzyl alcohol, isopropyl myristate, diisopropyl adipate, crotamiton, potato oil, camellia oil, castor oil, and olive oil.
[0071] 色素としては、例えば、赤色 2号 (アマランス)、赤色 3号 (エリス口シン)、赤色 102号 [0071] Examples of the dye include Red No. 2 (Amaranth), Red No. 3 (Eris Mouth Shin), Red No. 102
(ニューコクシン)、赤色 104号の(1) (フロキシン B)、赤色 105号の(1) (ローズベン ガル)、赤色 106号 (アシッドレッド)、黄色 4号 (タートラジン)、黄色 5号 (サンセットェ ロー FCF)、緑色 3号(ファストグリーン FCF)、青色 1号(ブリリアントブルー FCF)、青 色 2号 (インジゴ力ノレミン)等が挙げられる。 (New Coccin), Red No. 104 (1) (Phloxin B), Red No. 105 (1) (Rose Bengal), Red No. 106 (Acid Red), Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset) Low FCF), Green No. 3 (Fast Green FCF), Blue No. 1 (Brilliant Blue FCF), Blue No. 2 (Indigo Power Noremin) and the like.
[0072] 香料としては、例えば、ハツ力油、ケィヒ油、チヨウジ油、ウイキヨゥ油、ヒマシ油、テレ ピン油、ユーカリ油、オレンジ油、ラベンダー油、レモン油、ローズ油、レモングラス油 等やローズマリー、セージ等の植物抽出物等が挙げられる。 [0072] Examples of the fragrance include heart oil, keich oil, cinnamon oil, fennel oil, castor oil, turpentine oil, eucalyptus oil, orange oil, lavender oil, lemon oil, rose oil, lemongrass oil and the like. And plant extracts such as marie and sage.
[0073] 紫外線吸収剤としては、例えば、パラアミノ安息香酸、パラアミノ安息香酸エステル 、パラジメチルァミノ安息香酸ァミル、サリチル酸エステル、アントラ-ル酸メンチル、 ゥンベリフエロン、エスクリン、ケィ皮酸ベンジル、シノキサート、グアイァズレン、ゥロカ ニン酸、 2— (2—ヒドロキシ一 5—メチルフエ-ル)ベンゾトリァゾール、 4—メトキシべ ンゾフエノン、 2—ヒドロキシー4ーメトキシベンゾフエノン、ジォキシベンゾン、ォクタべ ンゾン、ジヒドロキシジメトキシベンゾフエノン、スリソベンゾン、ベンゾレソルシノール、 ォクチルジメチルパラァミノべンゾエート、ェチルへキシルパラメトキシサイナメート、 及びブチルメトキシジベンゾィルメタン等が挙げられる。 [0073] Examples of the ultraviolet absorber include, for example, paraaminobenzoic acid, paraaminobenzoic acid ester, paradimethylaminobenzoic acid amyl, salicylate, menthyl anthralate, pumbelliferone, esculin, benzyl cinnamate, sinoxate, guaiazulene, Perocanic acid, 2- (2-hydroxy-15-methylphenyl) benzotriazole, 4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone, dioxybenzone, octabenzone, dihydroxydimethoxybenzophenone, slisobenzone Benzoresorcinol, octyldimethylparaaminobenzoate, ethylhexylparamethoxycinnamate, and butylmethoxydibenzoylmethane.
[0074] 無機充填剤としては、例えば、炭酸カルシウム、炭酸マグネシウム、ケィ酸塩 (例え ば、ケィ酸アルミニウム、ケィ酸マグネシウム等)、ケィ酸、硫酸バリウム、硫酸カルシゥ ム、亜鉛酸カルシウム、酸化亜鉛、酸ィ匕チタン等が挙げられる。 [0074] Examples of the inorganic filler include calcium carbonate, magnesium carbonate, silicates (eg, aluminum silicate, magnesium silicate, and the like), citric acid, barium sulfate, calcium sulfate, calcium zincate, and zinc oxide. And titanium oxide.
[0075] pH調整剤としては、例えば、酢酸、蟻酸、乳酸、酒石酸、シユウ酸、安息香酸、ダリ コール酸、リンゴ酸、クェン酸、塩酸、硝酸、硫酸、水酸化ナトリウム、水酸化カルシゥ ム、メチルァミン、ェチルァミン、プロピルァミン、ジメチルァミン、ジェチルァミン、ジプ 口ピルァミン、トリメチルァミン、トリエチルァミン、トリプロピルァミン、モノメタノールアミ ン、モノエタノールァミン、モノプロパノールァミン、ジメタノールァミン、ジエタノールァ ミン、ジプロパノールァミン、トリメタノールァミン、トリエタノールァミン、トリプロパノ一 ルァミン、クェン酸バッファー、リン酸バッファー、グリシンバッファー、酢酸バッファー その他の緩衝液等が挙げられる。 [0075] Examples of the pH adjuster include acetic acid, formic acid, lactic acid, tartaric acid, oxalic acid, benzoic acid, dalicholic acid, malic acid, citric acid, hydrochloric acid, nitric acid, sulfuric acid, sodium hydroxide, calcium hydroxide, Methylamine, ethylamine, propylamine, dimethylamine, getylamine, dipyramine, trimethylamine, triethylamine, tripropylamine, monomethanolamine, monoethanolamine, monopropanolamine, dimethanolamine, diethanolamine , Dipropanolamine, trimethanolamine, triethanolamine, tripropanol Lumin, citrate buffer, phosphate buffer, glycine buffer, acetate buffer and other buffers.
[0076] 上述した成分を含有する膏体基剤から形成されるシート状含水膏体 3は、支持体 2 上に配置される。本実施形態の貼付剤 1に用いられる支持体 2としては、シート状含 水膏体 3を支持し得るものであれば特に制限されず、伸縮性又は非伸縮性の支持体 を用いることができる。 [0076] The sheet-shaped hydrogel 3 formed from the plaster base containing the above-described components is disposed on the support 2. The support 2 used for the patch 1 of the present embodiment is not particularly limited as long as it can support the sheet-like hydrogel 3, and a stretchable or non-stretchable support can be used. .
[0077] 支持体 2としては、具体的には、ポリウレタン、ポリエステル、ポリプロピレン、ポリ酢 酸ビュル、ポリ塩化ビ-リデン、ポリエチレン、ポリエチレンテレフタレート、アルミ-ゥ ムシート、ナイロン、アクリル、綿、レーヨン、アセテート等の合成繊維又は天然繊維、 あるいはこれらの繊維を複合して織布又は不織布とした繊維シート、さら〖こはこれらと 水蒸気透過性を有するフィルムとの複合素材等力 なる繊維シートが挙げられる。 [0077] Examples of the support 2 include polyurethane, polyester, polypropylene, poly (vinyl acetate), polyvinylidene chloride, polyethylene, polyethylene terephthalate, aluminum sheet, nylon, acrylic, cotton, rayon, and acetate. And the like. Synthetic fibers or natural fibers such as those described above, or a fiber sheet formed by combining these fibers into a woven or nonwoven fabric, and a fiber sheet which is a composite material of these and a film having water vapor permeability.
[0078] これらの中でも、安全性、汎用性及び伸縮性の点から、ポリエステル、ポリエチレン 、ポリエチレンテレフタレートからなる織布又は不織布の繊維シートが好ましぐポリエ チレンテレフタレートからなる織布又は不織布の繊維シートがより好まし 、。このような 繊維シートは厚みのあるものであっても、柔軟性を有し、皮膚に追従しやすぐ皮膚 刺激性の低いものである。さらに、このような繊維シートを用いることにより適度な自己 支持性を有する貼付剤を得ることが可能である。 [0078] Among these, a woven or nonwoven fiber sheet made of polyethylene terephthalate, which is preferably a woven or nonwoven fiber sheet made of polyester, polyethylene, or polyethylene terephthalate in terms of safety, versatility, and stretchability Is more preferred,. Such a fiber sheet has flexibility, even if it is thick, and follows the skin and has low skin irritation immediately. Furthermore, by using such a fiber sheet, it is possible to obtain a patch having an appropriate self-supporting property.
[0079] さらに、本実施形態の貼付剤においては、支持体がポリエチレン不織布である場合 には、膏体力 の水分の蒸発が抑制できるため、さらに潤い感が向上する。 Further, in the patch of the present embodiment, when the support is a polyethylene non-woven fabric, the moisture of the plaster can be suppressed from evaporating, so that the feeling of moisture is further improved.
[0080] また、貼付剤 1は、シート状含水膏体 3上に貼着された剥離シート 4を備えている。こ のような剥離シート 4としては、例えば、ポリエチレンテレフタレート等のポリエステル、 ポリ塩ィ匕ビュル、ポリ塩ィ匕ビユリデン等のフィルム、上質紙とポリオレフインとのラミネ 一トフイルム等が挙げられる。これらの剥離シートは、シート状含水膏体 3と接触する 側の面にシリコーン処理を施すと、貼付剤 1から剥離シート 4を剥離する際の作業容 易性が高められるので好ましい。 [0080] Further, the adhesive preparation 1 includes a release sheet 4 adhered on the sheet-like hydrogel body 3. Examples of such a release sheet 4 include polyester such as polyethylene terephthalate, films such as polychloride butyl, polychloride violetidene, and laminating film of high quality paper and polyolefin. These release sheets are preferably subjected to silicone treatment on the surface in contact with the sheet-shaped hydrogel body 3 because the workability when the release sheet 4 is released from the patch 1 is improved.
[0081] 次に、本実施形態の貼付剤 1の製造方法について説明する。 Next, a method for producing the patch 1 of the present embodiment will be described.
[0082] 先ず、精製水に、水溶性高分子、及び薬効成分などの各成分を添加し、これらを撹 拌混合することにより膏体基剤を調製する。撹拌の条件等については、配合する水 溶性高分子の種類に応じて適宜設定すればよいが、例えば、易溶性寒天を用いる 場合には、 65〜85°Cの精製水に添加して、 5〜15分間撹拌することにより寒天は十 分に溶解し、膏体基剤を調製することができる。 First, a plaster base is prepared by adding each component such as a water-soluble polymer and a medicinal ingredient to purified water and stirring and mixing these components. For stirring conditions, etc., It may be set appropriately according to the type of the soluble polymer.For example, when easily soluble agar is used, the agar is added to purified water at 65 to 85 ° C and stirred for 5 to 15 minutes to reduce the agar. In minutes to prepare a plaster base.
[0083] 次に、得られた膏体基剤を、支持体上に塗布して塗膜を形成し、さらに塗膜の上に 剥離シートを張り合わせる。これを室温で数日間保管し、水溶性高分子を十分に架 橋させることによりシート状含水膏体を形成する。本実施形態においては、形成され るシート状含水膏体の膜厚力 0. 8〜1. 6mmの範囲であることが好ましい。膜厚が 、 0. 8mm未満であると、膜厚が薄すぎるため、十分な粘着力が得られなくなる傾向 にあり、 1. 6mmを超えると、膜厚が薄すぎるため、使用時に剥がれやすくなる傾向 にある。 [0083] Next, the obtained plaster base is applied on a support to form a coating film, and a release sheet is laminated on the coating film. This is stored at room temperature for several days, and the water-soluble polymer is sufficiently crosslinked to form a sheet-like hydrogel. In the present embodiment, it is preferable that the thickness of the formed hydrogel sheet is in the range of 0.8 to 1.6 mm. If the film thickness is less than 0.8 mm, the film thickness is too thin, so that sufficient adhesive strength tends not to be obtained. If the film thickness is more than 1.6 mm, the film thickness is too thin, and the film tends to peel off during use. There is a tendency.
[0084] シート状含水膏体が形成された後、所定の形状に裁断することにより貼付剤が得ら れる。 [0084] After the sheet-like water-containing plaster is formed, the patch is obtained by cutting it into a predetermined shape.
[0085] また、本実施形態の貼付剤 1の製造方法では、膏体基剤の調製において、水溶性 高分子として、易溶性寒天と、ポリアクリル酸及び Z又はその塩とを含有させることが 好ましい。この場合、易溶性寒天が溶解に高温(90°C以上)を必要としないため、上 述した揮発性又は熱分解性の成分を効率よく貼付剤に配合することができる。また、 揮発性又は熱分解性成分を配合するために、寒天の溶解液を冷却する装置、エネ ルギ一、時間等が必要なぐ製造工程の簡略化も達成できる。さらには、製造時にお V、て、揮発性又は熱分解性成分のみならず水分の蒸発をも十分に抑制できるので、 形成されるシート状含水膏体における各成分の含有割合を上記した範囲により容易 に入れることが可能となり、潤い感などの使用感に十分優れるとともに、膏体からの水 分の滲み出しが十分に低減されており、且つ十分な粘着力を有する貼付剤を歩留ま りょく得ることが可會となる。 [0085] In the method for producing patch 1 of the present embodiment, in the preparation of the plaster base, as the water-soluble polymer, easily soluble agar, and polyacrylic acid and Z or a salt thereof are contained. preferable. In this case, since the easily soluble agar does not require a high temperature (90 ° C. or higher) for dissolution, the volatile or thermally decomposable component described above can be efficiently incorporated into the patch. In addition, it is possible to simplify the manufacturing process, which requires an apparatus for cooling the solution of agar, energy, time and the like in order to mix volatile or thermally decomposable components. Furthermore, since the evaporation of water as well as volatile or thermally decomposable components can be sufficiently suppressed at the time of production, the content ratio of each component in the formed sheet-like hydrogel is determined according to the above range. It is easy to put in, and it has a sufficiently excellent usability such as moistness, and has sufficiently reduced oozing of water from the plaster, and has a sufficient adhesive strength to produce a patch. It is possible to get it.
[0086] 以上、本発明の貼付剤の好適な実施形態、並びに本発明の貼付剤の製造方法に ついて説明したが、本発明は上記実施形態に限定されるものではない。 [0086] Although the preferred embodiment of the patch of the present invention and the method for producing the patch of the present invention have been described above, the present invention is not limited to the above embodiment.
[0087] 例えば、貼付剤の形状を、円形、楕円形等の形状としてもよい。また、穴や切れ目 等を施してもよい。さら〖こ、貼付剤が使用される身体の部位に応じて適宜設計された 形状とすることができる。例えば、顔に貼付できるよう、顔面の形状に裁断し、適宜目 、鼻、口および顎を適当な形状に切ったものが挙げられる。 [0087] For example, the patch may have a circular or elliptical shape. Also, holes or cuts may be provided. Further, the shape can be appropriately designed according to the body part where the patch is used. For example, cut it into a facial shape so that it can be attached to the face, , Nose, mouth and chin cut into appropriate shapes.
[0088] また、貼付剤の製造方法にお!、て、膏体基剤を剥離シート上に塗布してシート状含 水膏体を形成してから、支持体をシート状含水膏体に張り合わせてもよ ヽ。 [0088] Further, in the method for producing a patch, a paste base is applied onto a release sheet to form a sheet-like hydrous body, and then the support is laminated to the sheet-like hydrous body.て も
[0089] 本発明の貼付剤は、医薬品若しくはそれに類するパップ剤、冷却シート、化粧品若 しくはそれに類するパック剤等に利用することができる。 [0089] The patch of the present invention can be used as a pharmaceutical or a poultice similar thereto, a cooling sheet, a cosmetic or a similar pack, and the like.
実施例 Example
[0090] (実施例 1) (Example 1)
精製水 79. 95質量部に合成ケィ酸アルミニウム 1. 0質量部を分散し、これにポリビ -ルピロリドン 1. 0質量部を添カ卩し、次いで、ポリエチレングリコール 3. 0質量部と易 溶性寒天 (伊那食品工業社製、商品名「UP— 37K」、ゼリー強度:700g/cm2) 0. 4質量部との混合物及びェデト酸ナトリウム 0. 25質量部を添加した。更に、ポリアタリ ル酸ナトリウム 7. 0質量部と、メタケイ酸アルミン酸マグネシウム 0. 3質量部と、ポリエ チレングリコール 7. 0質量部との混合物を添加し、均一な溶液になるまで撹拌した。 その後、この溶液に酒石酸 0. 1質量部を添加し、さらに撹拌することにより膏体基剤 を調製した。表 1に、調製した膏体基剤の各成分及び配合割合を示す。なお、表 1中 の数値は質量%で表されている。また、膏体基剤の pHは、 6. 4であった。 1.0 part by mass of synthetic aluminum silicate was dispersed in 79.95 parts by mass of purified water, and 1.0 part by mass of polyvinylpyrrolidone was added thereto, and then the mixture was readily soluble in 3.0 parts by mass of polyethylene glycol. A mixture with 0.4 parts by mass of agar (trade name “UP-37K”, manufactured by Ina Food Industry Co., Ltd., jelly strength: 700 g / cm 2 ) and 0.25 parts by mass of sodium edetate were added. Further, a mixture of 7.0 parts by mass of sodium polyatalylate, 0.3 parts by mass of magnesium aluminate metasilicate, and 7.0 parts by mass of polyethylene glycol was added and stirred until a uniform solution was obtained. Thereafter, 0.1 part by mass of tartaric acid was added to this solution, and the mixture was further stirred to prepare a plaster base. Table 1 shows the components and mixing ratios of the prepared plaster bases. The values in Table 1 are expressed in mass%. The pH of the plaster base was 6.4.
[0091] [表 1] [0091] [Table 1]
[0092] 次に、得られた膏体基剤を、支持体としての日本バイリーン社製の布(25cm X 25c m)上に厚さが 1. 4mmとなるように展延し、塗膜を形成した。さら〖こ、この塗膜上に剥 離フィルムを貼り合わせたものを室温で保存してシート状含水膏体を形成すること〖こ より、製品として出荷可能な貼付剤を得た。貼付剤が出荷可能となる判断基準は次 のとおりである。 [0092] Next, the obtained plaster base was spread on a cloth (25 cm x 25 cm) manufactured by Nippon Vileen Co., Ltd. as a support so as to have a thickness of 1.4 mm. Formed. Further, a product obtained by attaching a release film to the coating film was stored at room temperature to form a sheet-like hydrogel, thereby obtaining a patch which can be shipped as a product. The criteria for the patch to be ready for shipment are as follows.
[0093] シート状含水膏体の膏体強度 (ゼリー強度)が、経時で一定となった時点を出荷可 能と判断した。なお、膏体基剤の調製を始めてから、出荷可能となる時点までの日数 (リードタイム)を表 1に示す。 [0094] また、得られた貼付剤について、シート状含水膏体の粘着力を JIS Z 0237 ロー リングボールタック試験に基づき測定した。結果を表 1に示す。 [0093] It was determined that shipment was possible when the plaster strength (jelly strength) of the sheet-like hydrous plaster became constant over time. Table 1 shows the number of days (lead time) from the start of preparation of the plaster base to the point where it can be shipped. [0094] Further, with respect to the obtained patch, the adhesive strength of the sheet-shaped hydrogel was measured based on the JIS Z 0237 rolling ball tack test. Table 1 shows the results.
[0095] さらに、得られた貼付剤のシート状含水膏体からの水分の滲み出しについて、下記 基準にしたがって評価した。結果を表 1に示す。 [0095] Further, the exudation of water from the sheet-like hydrogel body of the obtained patch was evaluated according to the following criteria. The results are shown in Table 1.
「なし」:支持体クロスの変色、或いは支持体クロス側への水のしみ出しが見られない "None": No discoloration of the support cloth or seepage of water on the support cloth side
「あり」:支持体クロスの変色、或いは支持体クロス側への水のしみ出しが見られる。 "Yes": Discoloration of the support cloth or seepage of water to the support cloth side is observed.
[0096] また、得られた貼付剤を顔面に貼付した際の使用感 (潤 、感、ベたつきの有無)に ついて、問題があった場合はそれを表 1に記載した。特に問題がなければ、記号「〇[0096] In addition, if there was a problem with the feeling of use (moistness, feeling, presence or absence of stickiness) when the obtained patch was applied to the face, it was described in Table 1. If there is no problem, the symbol "〇
」を記載した。 Was described.
[0097] (実施例 2〜4) (Examples 2 to 4)
膏体基剤の調製において、表 1に示す成分組成としたこと以外は実施例 1と同様に して膏体基剤を調製した。なお、膏体基剤の pHは、 6. 3〜6. 5であった。 In preparing the plaster base, a plaster base was prepared in the same manner as in Example 1 except that the component compositions shown in Table 1 were used. The pH of the plaster base was 6.3 to 6.5.
[0098] 得られた膏体基剤を用い、実施例 1と同様にして貼付剤を得た。なお、膏体基剤の 調製を始めてから、出荷可能となる時点までの日数 (リードタイム)を表 1に示す。さら に、得られた貼付剤について、実施例 1と同様の評価を行った。結果を表 1に示す。 Using the obtained plaster base, a patch was obtained in the same manner as in Example 1. Table 1 shows the number of days (lead time) from the start of preparation of the plaster base to the point where it can be shipped. Further, the obtained patch was evaluated in the same manner as in Example 1. The results are shown in Table 1.
[0099] (比較例 1〜3) [0099] (Comparative Examples 1-3)
膏体基剤の調製において、ゼラチンを用い、表 2に示す成分組成としたこと以外、 実施例 1と同様にして貼付剤を得た。 A patch was obtained in the same manner as in Example 1 except that gelatin was used in the preparation of the plaster base and the component composition was as shown in Table 2.
[0100] [表 2] [0100] [Table 2]
比較例 1 比較例 2 比較例 3 比較例 4 比較例 5 比較例 6 比較例 7 ゼラチン 1.0 1. 2 1. 0 ― ― ― ― ポリアクリル酸 ― ― ― ― ― 1. 5 ― ポリアクリル酸 Na 6.0 3. 0 9.0 7.0 1. 0 4. 0 10.0 キサンタンガム ― ― 0. 5 ― 0. 5 ― ― ポリビニル 一 一 一 1. 5 一 一 一 ピロリドン Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Comparative Example 7 Gelatin 1.0 1.2 1 0----Polyacrylic acid------1.5-Polyacrylic acid Na 6.0 3.0 9.0 7.0 1. 0 4.0 10.0 Xanthan gum--0.5-0.5--Polyvinyl 1.1 1.5 1.1 Pyrrolidone
易溶性寒天 ― ― 0. 5 0.4 0. 7 1. 0 1.0 合成ケィ酸 4.0 5. 0 4. 0 1.0 1. 0 3. 0 4. 0 アルミニウム Highly soluble agar ― ― 0.5 0.4 0.7 0.7 1.0 Synthetic keic acid 4.0 5.0 4.0 1.0 1.0 3.0 4.0 Aluminum
ポリエチレン 8.0 ― 10.0 10. 0 8. 0 8.0 6.0 グリコ一ル Polyethylene 8.0 ― 10.0 10.0 8.0 0 8.0 6.0 Glycol
グリセリン ― 8. 0 5. 0 ― ― ― 4.0 メタケイ酸アルミン酸 ― ― ― 0. 30 0. 30 ― ― マグネシウム Glycerin ― 8.0 5.0 ― ― ― 4.0 Aluminic acid metasilicate ― ― ― 0.30 0.30 ― ― Magnesium
ケィ酸アルミン酸 一 一 0. 6 O C一 一 一 0. 6 マグネシウム Aluminic acid silicate 0.1 0.6 O C 1.1 0.6 Magnesium
乾燥アルミン酸 0. 25 0. 70 ― ― ― 0. 30 ― マグネシウム Dry aluminate 0.25 0.70 ― ― ― 0.30 ― Magnesium
ェデト酸ナトリウム 0. 40 0. 45 0. 35 0. 25 0. 20 Sodium edetate 0.40 0.45 0.35 0.25 0.20
― d ― D
乳酸 0. 10 ― ― ― 0. 10 0. 10 Lactic acid 0.10 ― ― ― 0.10 0.10
O O
酒石酸 ― 0. 10 0. 10 0. 10 0. 10 ― ― ソルビ! ル ― ― ― ― ― 10.0 5.0 o 精製水 80. 25 81. 55 88. 20 71. 80 69. 10 o ぐ評価 > Tartaric acid ― 0.10 0.10 0.10 0.10 ― ― Sorbyl! ― ― ― ― ― 10.0 5.0 o Purified water 80.25 81.55 88.20 71.80 69.10 o
膏体からの滲出 あり あ y あり なし あり なし なし 粘着性 (mm) ― ― ― 20. 5 ― 61. 1 58. 2 使用感 〇 o 〇 ベたつき o 〇 潤い感 がある が低い リードタイム(日) ― ― ― 14 ― 14 16 Exudation from plaster Yes Yes Yes No Yes No No No Adhesiveness (mm) ― ― ― 20.5-61. 1 58.2 Usability 〇 o 〇 Sticky o が あ る Moist but low lead time ( Days) ― ― ― 14 ― 14 16
[0101] 得られた貼付剤について、実施例 1と同様の評価を行った。結果を表 2に示す。な お、比較例 1〜3の貼付剤は、シート状含水膏体からの水分の滲み出しが生じたため 、粘着性及びリードタイムは測定することができな力つた。 [0101] The obtained patches were evaluated in the same manner as in Example 1. Table 2 shows the results. In the patches of Comparative Examples 1 to 3, the osmosis of water from the hydrogel sheet-like sheet occurred, so that the adhesiveness and the lead time could not be measured.
[0102] (比較例 4〜7) [0102] (Comparative Examples 4 to 7)
膏体基剤の調製において、表 2に示す成分組成としたこと以外、実施例 1と同様に して貼付剤を得た。 In preparing the plaster base, the same as in Example 1 except that the component compositions shown in Table 2 were used. To give a patch.
[0103] 得られた貼付剤につ!ヽて、実施例 1と同様の評価を行った。結果を表 2に示す。な お、比較例 5の貼付剤は、シート状含水膏体からの水分の滲み出しが生じたため、粘 着性及びリードタイムは測定することができな力つた。 [0103] The same evaluation as in Example 1 was performed on the obtained patch. Table 2 shows the results. In the patch of Comparative Example 5, the adhesiveness and the lead time were too strong to measure because of the oozing of water from the hydrogel sheet.
[0104] 表 1に示すように、実施例 1〜4の貼付剤は、使用感に優れ、膏体からの水分の滲 み出しが十分に低減されており、かつ十分な粘着力を有することが確認された。一方 、ゼラチンを用いた比較例 1〜3の貼付剤は、膏体力 の水分の滲み出しが生じた。 また、本発明の条件を満たさな!/、膏体基剤から形成されたシート状含水膏体を有す る比較例 4〜7の貼付剤は、使用感、膏体力 の水分の滲み出しの低減、粘着力の V、ずれかが不十分であることが確認された。 [0104] As shown in Table 1, the patches of Examples 1 to 4 had excellent usability, had sufficiently reduced water seepage from the plaster, and had sufficient adhesive strength. Was confirmed. On the other hand, in the patches of Comparative Examples 1 to 3 using gelatin, the oozing of water was observed as a plaster strength. Further, the patches of Comparative Examples 4 to 7 having a sheet-like hydrous plaster formed from a plaster base did not satisfy the conditions of the present invention! It was confirmed that the reduction, the V of the adhesive strength, and the deviation were insufficient.
[0105] 更に、実施例 1〜4の貼付剤は、リードタイムが 8〜11日であり、一方、比較例 4、 6 及び 7の貼付剤のリードタイムは 14〜16日であった。このこと力ら、実施例 1〜4の貼 付剤は生産性に優れていることが分力つた。 Further, the patches of Examples 1 to 4 had a lead time of 8 to 11 days, whereas the patches of Comparative Examples 4, 6 and 7 had a lead time of 14 to 16 days. From these facts, it was a component that the patches of Examples 1 to 4 were excellent in productivity.
産業上の利用可能性 Industrial applicability
[0106] 本発明によれば、所望の成分を含有し所望の pHを有する配合であっても、潤 ヽ感 などの使用感に十分優れると共に、膏体からの水分の滲み出しが十分に低減されて おり、かつ十分な粘着力を有する貼付剤を提供することができる。 [0106] According to the present invention, even a composition containing a desired component and having a desired pH is sufficiently excellent in usability such as moist feeling and sufficiently reduces oozing of moisture from the plaster. Thus, a patch having sufficient adhesive strength can be provided.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006512821A JP4744439B2 (en) | 2004-04-28 | 2005-04-27 | Patch |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004134005 | 2004-04-28 | ||
| JP2004-134005 | 2004-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005105060A1 true WO2005105060A1 (en) | 2005-11-10 |
Family
ID=35241415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/008035 Ceased WO2005105060A1 (en) | 2004-04-28 | 2005-04-27 | Plaster |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP4744439B2 (en) |
| TW (1) | TW200602008A (en) |
| WO (1) | WO2005105060A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007034736A1 (en) * | 2005-09-20 | 2007-03-29 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive skin patch |
| JPWO2005105150A1 (en) * | 2004-04-28 | 2008-03-13 | 久光製薬株式会社 | Patch |
| WO2012105618A1 (en) * | 2011-02-02 | 2012-08-09 | 日東電工株式会社 | Patch preparation |
| US9163164B2 (en) | 2012-01-27 | 2015-10-20 | Hisamitsu Pharmaceutical Co., Inc. | Support film for tape and tape |
| TWI505819B (en) * | 2010-07-29 | 2015-11-01 | Hisamitsu Pharmaceutical Co | Medical patch |
| US9340709B2 (en) | 2010-07-29 | 2016-05-17 | Hisamitsu Pharmaceutical Co., Inc. | Support film for tape and tape |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59196814A (en) * | 1983-04-21 | 1984-11-08 | Nippon Kayaku Co Ltd | Sheetlike "nifedipine(r)" pharmaceutical |
| JP2000026299A (en) * | 1998-07-10 | 2000-01-25 | Hisamitsu Pharmaceut Co Inc | Steroid-containing cataplasm and its production |
| JP2003518008A (en) * | 1999-07-06 | 2003-06-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | Preformed gel sheet |
| JP2003518010A (en) * | 1999-07-06 | 2003-06-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | Preformed self-adhesive sheet-like device suitable for topical application |
| JP2005008613A (en) * | 2003-05-28 | 2005-01-13 | Kanae Technos:Kk | Gel sheet for pack |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2504776B2 (en) * | 1987-06-23 | 1996-06-05 | 伊那食品工業株式会社 | Agar manufacturing method |
| ES2408007T3 (en) * | 2004-04-28 | 2013-06-17 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive material |
-
2005
- 2005-04-27 WO PCT/JP2005/008035 patent/WO2005105060A1/en not_active Ceased
- 2005-04-27 JP JP2006512821A patent/JP4744439B2/en not_active Expired - Lifetime
- 2005-04-28 TW TW094113709A patent/TW200602008A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59196814A (en) * | 1983-04-21 | 1984-11-08 | Nippon Kayaku Co Ltd | Sheetlike "nifedipine(r)" pharmaceutical |
| JP2000026299A (en) * | 1998-07-10 | 2000-01-25 | Hisamitsu Pharmaceut Co Inc | Steroid-containing cataplasm and its production |
| JP2003518008A (en) * | 1999-07-06 | 2003-06-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | Preformed gel sheet |
| JP2003518010A (en) * | 1999-07-06 | 2003-06-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | Preformed self-adhesive sheet-like device suitable for topical application |
| JP2005008613A (en) * | 2003-05-28 | 2005-01-13 | Kanae Technos:Kk | Gel sheet for pack |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005105150A1 (en) * | 2004-04-28 | 2008-03-13 | 久光製薬株式会社 | Patch |
| JP4703559B2 (en) * | 2004-04-28 | 2011-06-15 | 久光製薬株式会社 | Patch |
| US7998590B2 (en) | 2004-04-28 | 2011-08-16 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive material |
| WO2007034736A1 (en) * | 2005-09-20 | 2007-03-29 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive skin patch |
| CN101252923B (en) * | 2005-09-20 | 2010-11-03 | 久光制药株式会社 | patch |
| TWI505819B (en) * | 2010-07-29 | 2015-11-01 | Hisamitsu Pharmaceutical Co | Medical patch |
| US9340709B2 (en) | 2010-07-29 | 2016-05-17 | Hisamitsu Pharmaceutical Co., Inc. | Support film for tape and tape |
| WO2012105618A1 (en) * | 2011-02-02 | 2012-08-09 | 日東電工株式会社 | Patch preparation |
| JP2012176942A (en) * | 2011-02-02 | 2012-09-13 | Nitto Denko Corp | Patch preparation |
| US9138419B2 (en) | 2011-02-02 | 2015-09-22 | Nitto Denko Corporation | Patch preparation |
| US9163164B2 (en) | 2012-01-27 | 2015-10-20 | Hisamitsu Pharmaceutical Co., Inc. | Support film for tape and tape |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4744439B2 (en) | 2011-08-10 |
| TW200602008A (en) | 2006-01-16 |
| JPWO2005105060A1 (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4467437B2 (en) | Warm patch | |
| JP4324465B2 (en) | Sheet patch | |
| JP4398158B2 (en) | Patch | |
| KR100647480B1 (en) | Patch | |
| CN103796646B (en) | Aqueous patch | |
| WO2002032431A1 (en) | Compositions for external preparations | |
| JP4703559B2 (en) | Patch | |
| JP4990150B2 (en) | Patch | |
| JPWO2000048580A1 (en) | Sheet-type patch | |
| EP2156827A1 (en) | Poultice and process for producing the poultice | |
| WO2005105060A1 (en) | Plaster | |
| JP3193161B2 (en) | Transdermal absorption preparation | |
| JP4592326B2 (en) | Patch | |
| JPH08113537A (en) | Indomethacin application agent | |
| CN115315262A (en) | Patch preparation | |
| JP2008094748A (en) | Cataplasm and method for producing cataplasm | |
| CA3236288A1 (en) | Occlusive plaster with flexible backing | |
| HK1141706A (en) | Poultice and process for producing the poultice | |
| JPWO2000006659A1 (en) | Adhesive composition, and moisture-permeable adhesive tape, adhesive drug composition, and adhesive tape preparation containing the composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006512821 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |